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A B S T R A C T
Background
Salt intake shows great promise as a modifiable risk factor for reducing heart disease incidence and delaying kidney function decline in
people with chronic kidney disease (CKD). However, a clear consensus of the benefits of reducing salt in people with CKD is lacking.
Objectives
This review evaluated the benefits and harms of altering dietary salt intake in people with CKD.
Search methods
We searched the Cochrane Renal Group’s Specialised Register to 13 January 2015 through contact with the Trials’ Search Co-ordinator
using search terms relevant to this review.
Selection criteria
We included randomised controlled trials (RCTs) that compared two or more levels of salt intake in people with any stage of CKD.
Data collection and analysis
Two authors independently assessed studies for eligibility and conducted risk of bias evaluation. Results were expressed as risk ratios
(RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) and 95% CI for continuous
outcomes. Mean effect sizes were calculated using the random-effects models.
Main results
We included eight studies (24 reports, 258 participants). Because duration of the included studies was too short (1 to 26 weeks) to test
the effect of salt restriction on endpoints such as mortality, cardiovascular events or CKD progression, changes in salt intake on blood
pressure and other secondary risk factors were applied. Three studies were parallel RCTs and five were cross-over studies. Selection bias
was low in five studies and unclear in three. Performance and detection biases were low in two studies and unclear in six. Attrition and
reporting biases were low in four studies and unclear in four. One study had the potential for high carryover effect; three had high risk
of bias from baseline characteristics (change of medication or diet) and two studies were industry funded.
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There was a significant reduction in 24 hour sodium excretion associated with low salt interventions (range 52 to 141 mmol) (8 studies,
258 participants: MD -105.86 mmol/d, 95%CI -119.20 to -92.51; I2 = 51%). Reducing salt intake significantly reduced systolic blood
pressure (8 studies, 258 participants: MD -8.75 mm Hg, 95% CI -11.33 to -6.16; I2 = 0%) and diastolic blood pressure (8 studies,
258 participants: MD -3.70 mm Hg, 95% CI -5.09 to -2.30; I2 = 0%). One study reported restricting salt intake reduced the risk of
oedema by 56%. Salt restriction significantly increased plasma renin activity (2 studies, 71 participants: MD 1.08 ng/mL/h, 95% CI
0.51 to 1.65; I2 = 0%) and serum aldosterone (2 studies, 71 participants: 6.20 ng/dL (95% CI 3.82 to 8.58; I2 = 0%). Antihypertensive
medication dosage was significantly reduced with a low salt diet (2 studies, 52 participants): RR 5.48, 95% CI 1.27 to 23.66; I2 =
0%). There was no significant difference in eGFR (2 studies, 68 participants: MD -1.14 mL/min/1.73 m2, 95% CI -4.38 to 2.11; I
2 = 0%), creatinine clearance (3 studies, 85 participants): MD -4.60 mL/min, 95% CI -11.78 to 2.57; I2 = 0%), serum creatinine (5
studies, 151 participants: MD 5.14 µmol/L, 95% CI -8.98 to 19.26; I2 = 59%) or body weight (5 studies, 139 participants: MD -1.46
kg; 95% CI -4.55 to 1.64; I2 = 0%). There was no significant change in total cholesterol in relation to salt restriction (3 studies, 105
participants: MD -0.23 mmol/L, 95% CI -0.57 to 0.10; I2 = 0%) or symptomatic hypotension (2 studies, 72 participants: RR 6.60,
95% CI 0.77 to 56.55; I2 = 0%). Salt restriction significantly reduced urinary protein excretion in all studies that reported proteinuria
as an outcome, however data could not be meta-analysed.
Authors’ conclusions
We found a critical evidence gap in long-term effects of salt restriction in people with CKD that meant we were unable to determine
the direct effects of sodium restriction on primary endpoints such as mortality and progression to end-stage kidney disease (ESKD).
We found that salt reduction in people with CKD reduced blood pressure considerably and consistently reduced proteinuria. If
such reductions could be maintained long-term, this effect may translate to clinically significant reductions in ESKD incidence and
cardiovascular events. Research into the long-term effects of sodium-restricted diet for people with CKD is warranted, as is investigation
into adherence to a low salt diet.
P L A I N L A N G U A G E S U M M A R Y
Altered dietary salt intake for people with chronic kidney disease
People with CKD are at increased risk of heart disease and deteriorating kidney health which can lead to need for dialysis or kidney
transplantation to survive. Reducing risk of heart disease and preserving kidney function are important treatment goals.
High salt intake is linked to risk factors for both heart disease and worsening kidney function, including high blood pressure, excess
protein in the urine (proteinuria) and fluid overload. It is thought to be particularly important for people with CKD to have a low salt
intake due to kidneys’ role in salt balance. We aimed to find out if altering salt in the diet was beneficial for people with CKD.
We searched the literature for studies that looked at the effects of restricting salt in the diets of people with CKD up to January 2015.
We found eight studies that involved 258 people which met our inclusion criteria. Study participants included people in the early stages
of CKD (six studies), who were on peritoneal dialysis (one study), or were kidney transplant recipients (one study). The average study
duration was six weeks, and ranged from one to 26 weeks. We did not find any studies that measured the effect of salt intake on the
incidence of death, heart disease, or need to begin dialysis.
We found that reducing salt intake reduced 24 hour sodium excretion, blood pressure. One study reported restricting salt intake
reduced the risk of oedema (swelling). Antihypertensive medication dosage was significantly reduced with a low salt diet. There was no
significant difference in kidney function measures or body weight. There was no significant change in total cholesterol or hypotension.
Long-term effects of salt restriction in people with CKD is lacking that meant we were unable to determine the direct effects of sodium
restriction on primary endpoints such as mortality and progression to end-stage kidney disease (ESKD). Research into the long-term
effects of sodium-restricted diet for people with CKD is warranted, as is investigation into adherence to low salt diet.
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B A C K G R O U N D
Description of the condition
Chronic kidney disease (CKD) is a major global public health
problem; data fromAustralia, theUnited States, Japan and Europe
indicate that CKD occurs in 6% to 13% of people (Chadban
2003; Coresh 2007; Meguid El Nahas 2005; Hamer 2006). CKD
prevalence is increasing rapidly and is thought to be related in part
to dramatic increases in rates of diabetes and hypertension - two
of the most common causes of CKD (Coresh 2007).
CKD is a progressive condition. People with end-stage kidney
disease (ESKD) require renal replacement therapy as dialysis or
kidney transplantation to survive. Mortality risk is 40 times higher
among people with ESKD compared with the general population
(Collins 2003). Annual healthcare costs of treating people with
ESKD have been estimated at about 10 times greater than the cost
of CKD management (Hunsicker 2004).
CKD is an independent risk factor for cardiovascular disease; peo-
ple with CKD are up to 10 times more likely to die of cardio-
vascular disease than progress to ESKD (Go 2004). Because both
cardiovascular disease and progression to ESKD may be delayed,
or possibly prevented, effective strategies to reduce these outcomes
are needed to improve patients’ prognoses and reduce healthcare
costs.
Description of the intervention
Excessive salt (sodium) intake is related to many risk factors for
cardiovascular disease and CKD progression. These include in-
creased blood pressure, fluid retention, proteinuria, inflammation,
oxidative stress and endothelial dysfunction (Al-Solaiman 2009;
Ritz 2009). Salt restriction has beneficial effects against risk fac-
tors such as hypertension and proteinuria over and above those
provided by antihypertensive medications (Vogt 2008). Despite
this, evidence suggests salt restriction is not adequately emphasised
for people with CKD (Thijssen 2008). A possible reason may be
that there is no clear consensus on the benefits of reducing salt
intake in people with CKD. Evidence-based practice guidelines
show inconsistencies in the ideal target for salt intake in people
with CKD, with salt targets ranging from less than 3.8 g of salt
(65 mmol sodium) per day to 6.5 g (110 mmol sodium) per day
(Ash 2006; USDA 2010).
How the intervention might work
Studies in the general population have consistently demonstrated
a link between dietary salt intake and blood pressure, particularly
among those who are salt sensitive (He 2013; Svetkey 1999). A
Cochrane review on reducing salt intake in people with diabetic
kidney disease showed considerable blood pressure reductions; sys-
tolic/diastolic bloodpressurewas lowered by 7/3mmHg (Suckling
2010).
It has also been suggested that salt has adverse effects independent
of blood pressure. Todd 2010 found arterial stiffness measured by
pulse wave velocity was significantly decreased independently of
blood pressure changes in hypertensive people on a low salt diet.
(Increased pulse wave velocity is a predictor of all-cause and car-
diovascular mortality (Guerin 2001)). Proteinuria, a risk factor for
both CKD progression and cardiovascular disease in people with
CKD, has also shown to be reduced by salt restriction independent
of blood pressure (Verhave 2004).
Why it is important to do this review
Salt intake shows great promise as a modifiable risk factor for re-
ducing cardiovascular risk and CKDprogression even among peo-
ple in the very early stages of the disease. However, clear consensus
of the benefits of reducing salt for people with CKD, and the opti-
mal target salt intake for this population, has yet to be established.
O B J E C T I V E S
This review evaluated the benefits and harms of altering dietary
salt intake in people with CKD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and quasi-RCTs
(RCTs in which allocation to treatment was obtained by alterna-
tion, use of alternate medical records, date of birth or other pre-
dictable methods) measuring the effect of low versus high salt in-
take in people with CKD.
Types of participants
Inclusion criteria
• Adults ( ≥ 18 years) with CKD (as defined by Kidney
Disease Outcomes Quality Initiative (K/DOQI) Clinical
Practice Guidelines) at all disease stages (NKF 2002)
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Exclusion criteria
• Pregnant women
• Children (aged up to 18 years).
Types of interventions
We planned to evaluate the following interventions.
• Comparing two or more differing levels of sodium intake
• Of at least one week duration
• Evaluated sodium intake estimated by 24 hour urinary
sodium excretion (24 h UNa) with a minimum difference in 24
h UNa of 34 mmol (2 g salt/d) achieved between allocated
interventions. Reduction in 24 h UNa was calculated as the
difference between UNa at the end of each intervention for
cross-over studies, and the difference in change between groups
from baseline to the end of intervention for parallel studies
• Where concomitant interventions such as antihypertensive
medication or other dietary modifications were used during the
study period, providing that these interventions were constant
throughout the low and high salt interventions.
Types of outcome measures
Primary outcomes
1. Cardiovascular mortality
2. All-cause mortality.
Secondary outcomes
1. Cardiovascular disease (coronary artery disease, heart
failure, cerebrovascular disease and peripheral vascular disease)
2. Progression to ESKD requiring dialysis or transplantation
3. 24 h UNa
4. Change in blood pressure (clinic and 24 hour measurement)
5. Change in arterial stiffness (pulse wave velocity and
augmentation index)
6. Change in kidney function measures (creatinine clearance
(CrCl), serum creatinine (SCr), proteinuria, glomerular filtration
rate (GFR))
7. Change in markers of fluid overload (brain natriuretic
peptide, weight, bio-impedance analysis)
8. Change in markers of oxidative stress or inflammation (C-
reactive protein, adipokines)
9. Adverse events: hypotensive episodes, undesirable change in
blood lipids (low density lipoprotein, high-density lipoprotein).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Renal Group’s Specialised Register to
13 January 2015 through contact with the Trials’ Search Co-or-
dinator using search terms relevant to this review. The Cochrane
Renal Group’s SpecialisedRegister contains studies identified from
the following sources.
• Monthly searches of the Cochrane Central Register of
Controlled Trials CENTRAL
• Weekly searches of MEDLINE OVID SP
• Hand-searching of renal-related journals and the
proceedings of major renal conferences
• Searching of the current year of EMBASE OVID SP
• Weekly current awareness alerts for selected renal journals
• Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the Specialised Register were identified
through search strategies for CENTRAL, MEDLINE, and EM-
BASE based on the scope of the Cochrane Renal Group. Details of
these strategies, as well as a list of handsearched journals, confer-
ence proceedings and current awareness alerts, are available in the
Specialised Register section of information about the Cochrane
Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and ab-
stracts of studies that may be relevant to the review. The titles
and abstracts were screened independently by two authors, who
discarded studies that were not applicable; however, studies and
reviews that might have included relevant data or information on
studies were retained initially. Two authors independently assessed
the retrieved abstracts, and if necessary, the full text of these studies
to determine which studies satisfied the inclusion criteria.
Data extraction and management
Data extraction was carried out independently by two authors us-
ing standard data extraction forms. Studies reported in non-En-
glish language journals were translated before assessment. Where
more than one publication of one study exists, reports were
grouped together and the publication with themost complete data
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was used in the analyses. Where relevant outcomes were only pub-
lished in earlier versions these data were used. Any discrepancies
between published versions were to be highlighted.
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?
◦ Participants and personnel
◦ Outcome assessors
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias? Two additional domains were addressed:
◦ Risk of carry over effect
◦ Potential bias from influence of confounding factors.
Measures of treatment effect
For dichotomous outcomes (cardiovascular mortality, all-cause
mortality, progression to ESKD, cardiovascular disease) results
were expressed as risk ratios (RR) with 95% confidence intervals
(CI). Where continuous scales of measurement were used to as-
sess the effects of treatment (blood pressure, pulse wave velocity,
augmentation index, CrCl, SCr, proteinuria, GFR, brain natri-
uretic peptide, weight, bio-impedance analysis, C-reactive protein,
adipokines) the mean difference (MD) was used, or the standard-
ised mean difference (SMD) if different scales were used. Studies
analysing change scores were included in meta-analysis along with
studies including endpoint data only.
Where change from baseline values were absent, these were cal-
culated by subtracting mean value at the end of the intervention
to baseline values (parallel studies) or subtracting the value from
the end of the higher sodium phase from the lower sodium phase
(cross-over studies) (Higgins 2011).
Unit of analysis issues
In cross-over studies, we determined the mean difference in out-
comes as the difference between the end of low salt and high salt
periods. We calculated the treatment effect as the difference be-
tween treatment groups’ change in outcomes from baseline for
parallel studies.
Dealing with missing data
Any further information required from the original author was
requested by written correspondence (e.g. emailing corresponding
author) and any relevant information obtained in this manner was
included in the review. Evaluation of important numerical data
such as screened, randomised subjects as well as intention-to-treat,
as-treated and per-protocol population were performed. Attrition
rates, for example drop-outs, losses to follow-up and withdrawals
were investigated. Issues of missing data and imputation methods
(for example, last-observation-carried-forward) were critically ap-
praised (Higgins 2011).
Assessment of heterogeneity
Heterogeneity was analysed using a Chi² test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance
and with the I² test (Higgins 2003). I² values of 25%, 50% and
75% correspond to low, medium and high levels of heterogeneity
(Higgins 2011).
Assessment of reporting biases
If possible, funnel plots were to be constructed to assess for the
potential existence of small study bias (Higgins 2011). There were
insufficient data to enable construction of funnel plots for this
review.
Data synthesis
Data were pooled using the random-effects model but the fixed-
effectmodel was also used to ensure robustness of themodel chosen
and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was used to explore possible sources of hetero-
geneity (such as intervention duration, levels of sodium intake).
Heterogeneity among participants could be related to age, stage of
CKD, presence of comorbidities (hypertension and diabetes) and
renal pathology (e.g. dialysed versus non-dialysed patients with
CKD).
Sensitivity analysis
Where necessary, we performed sensitivity analyses in order to
explore the influence of the following factors on effect size:
• repeating the analysis excluding unpublished studies
• repeating the analysis taking account of risk of bias, as
specified
• repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
• repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country.
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R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
The search identified 1066 records. After removal of duplicates
we assessed 985 records; of these, 915 were excluded based on the
title and abstract. We assessed the full text of the remaining 70
articles. We identified eight studies (24 reports; 261 participants)
that met our inclusion criteria (Figure 1).
Figure 1. Study flow diagram* 2 records were identified in a prepublication search and will be assessed in a
future update of this review
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Included studies
See Characteristics of included studies.
Of the eight included studies, six were cross-over (DUAAAL Study
2011; Fine 1997; Konishi 2001; LowSALT CKD Study 2012;
Ruilope 1992a; Vogt 2008) and two were parallel design stud-
ies (de Brito-Ashurst 2013; Keven 2006). Because the cross-over
studies did not repeat outcome measurement at the beginning
of each intervention (baseline for each intervention), the differ-
ence between values at the end of each intervention were used. de
Brito-Ashurst 2013 reported change from baseline for each group,
and these data were used for analysis. Keven 2006 did not present
data on change from baseline, and because there were no appro-
priate data available to impute standard deviations for change, dif-
ferences between values at the end of the intervention were used
for this review.
Two studies enrolled participants with ESKD (peritoneal dialysis
Fine 1997; post-transplant Keven 2006), and six enrolled partici-
pants in earlier stages of CKD (de Brito-Ashurst 2013; DUAAAL
Study 2011; Konishi 2001; LowSALT CKD Study 2012; Ruilope
1992a; Vogt 2008).
Median study duration was six weeks, ranging from one to 26
weeks.
A cut-off of four weeks was used to classify studies according to
intervention duration (short-term: fewer than four weeks; long-
term: four weeks or more). Three studies, two with one-week
interventions (Konishi 2001; Ruilope 1992a), and one with two-
week interventions (LowSALT CKD Study 2012), were classified
as short-term. We classified four studies as long-term (range: six
to 26 weeks) (de Brito-Ashurst 2013; Fine 1997; DUAAAL Study
2011; Keven 2006; Vogt 2008).
Three studies used sodium supplements to achieve difference in
sodium intake (Fine 1997; LowSALT CKD Study 2012; Ruilope
1992a); Konishi 2001 provided all food for participants; three
compared sodium restriction achieved through dietary counselling
with usual diet (de Brito-Ashurst 2013; DUAAAL Study 2011;
Keven2006) andVogt 2008 compared sodium restriction through
dietary counselling to a high salt version of the diet (aiming to
keep intake of other nutrients stable).
LowSALT CKDStudy 2012 applied dietary education techniques
to reduce sodium intake among participants by using sodium sup-
plements in the high salt intervention (120 mmol sodium) and
placebo in the low salt intervention. Ruilope 1992a used unspec-
ified means to achieve a very low sodium intake (17 mmol) with
170 mmol of supplemental sodium in the high salt intervention
versus 51 mmol of supplemental sodium in the low salt interven-
tion. Fine 1997 investigated usual diet with 60 mmol of supple-
mental sodium in the high salt intervention versus placebo in the
low salt intervention.
Two studies used concomitant interventions that remained stable
throughout the high and low salt phases. DUAAAL Study 2011
started all participants on lisinopril 40 mg/d and Ruilope 1992a
used verapamil 240mg/d. The protocol for Konishi 2001 included
cessation of all medications one week before the study.
Outcome reporting in included studies
All studiesmeasured 24 hour urinary sodium excretion as amarker
of sodium intake. Fine 1997, whose participants were receiving
peritoneal dialysis, added 24 hour urinary sodium to 24 hour
dialysate sodium to achieve a total value for urinary sodium excre-
tion, and this value was used for analysis. Fine 1997 and LowSALT
CKD Study 2012 included additional self-reported measures of
sodium intake, but to enhance comparability, we used sodium ex-
cretion as an intake marker.
All studies reported blood pressure measurements. Four studies
measured 24 hour ambulatory blood pressure (de Brito-Ashurst
2013;Konishi 2001; LowSALTCKDStudy 2012;Ruilope 1992a)
and four used clinic-assessed blood pressure. Two studiesmeasured
both clinic and 24 hour blood pressure (LowSALT CKD Study
2012; Ruilope 1992a); however 24 hour blood pressure was used
for our analyses.
Proteinuria data could not be entered into pooled analysis, but is
summarised in Table 1.
Excluded studies
We excluded 10 studies (39 reports) that did not meet our inclu-
sion criteria. Reasons for exclusion were: non-CKD population
(Forrester 2010; Suckling 2010b; Swift 2005); concomitant inter-
vention that was not stable between interventions (Esnault 2005;
Kauric-Klein 2012; Rupp 1978) or no randomised allocation to
low or high salt diet (De Nicola 2000; IDNT 2001; Mahmoodi
2011; Osanai 2002). No studies were excluded on the basis of not
reporting change in 24 hour urinary sodium excretion.
Studies awaiting classification
Two studies were identified during the final prepublication search
and will be assessed in a future update of this review (Hwang 2014;
Rodrigues Telini 2014).
Ongoing studies
Four studies (five reports) are ongoing and will be assessed once
they have been completed (Clark-Cutaia 2013; NCT00141609;
NCT00974636; NCT01015313).
Risk of bias in included studies
Figure 2 and Figure 3 summarise risk of bias assessment for the
included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.Studies were frequently assessed as having unclear or high risk of bias
for the risk of bias study domains with selection bias, performance bias, detection bias, and confounding bias
domains having the largest proportion of unclear/high risk of bias.
Allocation
All included studies were randomised. Investigators fromfive stud-
ies (de Brito-Ashurst 2013; Fine 1997; DUAAAL Study 2011;
LowSALT CKD Study 2012; Vogt 2008) provided further infor-
mation about the method of randomisation.
Blinding
Fine 1997 and LowSALT CKD Study 2012 were blinded, four
studies were open-label (de Brito-Ashurst 2013; DUAAAL Study
2011; Keven 2006; Vogt 2008); Konishi 2001 and Ruilope 1992a
did not describe blinding.
Incomplete outcome data
Konishi 2001 and Ruilope 1992a did not report participant attri-
tion. Fine 1997 reported significant attrition (37%), but did not
discuss if there were systematic differences between study com-
pleters and non-completers.
Selective reporting
Risk of reporting bias was unclear for three studies for which trial
registration or study protocol could not be located (Keven 2006;
Konishi 2001; Ruilope 1992a). We found that de Brito-Ashurst
2013 had incomplete data for some outcomes or evidence of in-
correct data; body weight data could not bemeta-analysed because
data provided (MD -4 kg, 95% CI -4 to -1) were not statistically
viable and corrected data were not available. Standard deviation
or P values for change in total body water were unavailable in the
publications for this study and were not provided by the authors;
hence, this outcome could not be entered into the analysis.
Other potential sources of bias
Carry over effect may have introduced bias in Konishi 2001 and
Ruilope 1992a; both were one week duration with no washout
between interventions. Ruilope 1992a introduced a new antihy-
pertensive medication at day 1 of the first intervention, increasing
risk of treatment order effect. Bias from confounders was classi-
fied as unclear or high risk for all studies, mostly due to lack of
measurement or failing to account for changes in dietary potas-
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sium intake, protein intake and/or weight loss between interven-
tions. We assessed that two studies were at high risk of bias in
relation to funding sources (Fine 1997; Vogt 2008); unclear in
four (DUAAAL Study 2011; Keven 2006; Konishi 2001; Ruilope
1992a); and low in two (de Brito-Ashurst 2013; LowSALT CKD
Study 2012).
Effects of interventions
Duration of the included studies was too short to test the efficacy
of salt restriction on endpoints such as mortality, cardiovascular
events or progression to ESKD. Therefore, changes in salt intake
on blood pressure and risk factors for cardiovascular disease and
ESKD were considered in evaluating the evidence for this review.
Urinary sodium excretion
There was a significant reduction in 24 hour sodium excretion
associated with low salt interventions (range 52 to 141 mmol)
(Analysis 1.1 (8 studies, 258 participants): MD -105.86 mmol/d,
95% CI -119.20 to -92.51; I2 = 51%).
Duration of studies
There was a significant reduction in 24 hour sodium excretion
associated with low salt interventions in both the short-term (
Analysis 1.1.1 (3 studies, 72 participants): MD -115.06 mmol/
d, 95% CI -132.50 to -97.62; I2 = 32%) and long-term studies
(Analysis 1.1.2 (5 studies, 186 participants): MD -99.11 mol/d,
95% CI -117.31 to -80.92; I2 = 47%). There was no significant
difference between the short-term and long-term studies (test for
subgroup differences: Chi2 = 1.54, df = 1 (P = 0.21); I2 = 35%).
Stage of chronic kidney disease
Six studies investigated people in early stages of CKD (de Brito-
Ashurst 2013; DUAAAL Study 2011; Konishi 2001; LowSALT
CKD Study 2012; Ruilope 1992a; Vogt 2008). There was a sig-
nificant reduction in 24 hour sodium excretion associated with
low salt interventions (Analysis 2.1.1 (6 studies, 206 participants):
MD -107.21 mmol/d, 95% CI -120.24 to -94.18; I2 = 51%).
Fine 1997 included 20 participants on peritoneal dialysis and re-
ported a non-significant decrease in 24-hour sodium excretion
with a low salt intervention (Analysis 2.1.2: MD -52.00 mmol/d,
95% CI -113.06 to 9.06).
Keven2006 included 32 post-transplant participants and reported
a significant decrease in 24-hour sodium excretion with a low salt
intervention (Analysis 2.1.3: MD -131.00 mmol/d, 95% CI -
194.21 to -67.79).
Blood pressure
All studies provided data on systolic and diastolic blood pressure
for analysis. Reducing salt intake significantly reduced systolic
blood pressure (Analysis 1.2 (8 studies, 258 participants): MD -
8.75 mm Hg, 95% CI -11.33 to -6.16; I2 = 0%) and diastolic
blood pressure (Analysis 1.3 (8 studies, 258 participants): MD -
3.70 mm Hg, 95% CI -5.09 to -2.30; I2 = 0%).
Duration of studies
In short-term studies, low salt interventions significantly reduced
systolic blood pressure (Analysis 1.2.1 (3 studies, 72 participants):
MD -7.18mmHg, 95%CI -11.48 to -2.89; I2 = 0%) and diastolic
blood pressure (Analysis 1.3.1 (3 studies, 72 participants): MD -
3.50 mm Hg, 95% CI -6.48 to -0.51; I2 = 0%).
In long-term studies, low salt interventions significantly reduced
systolic bloodpressure (Analysis 1.2.2 (5 studies, 186participants):
MD -9.64 mm Hg, 95% CI -12.88 to -6.40; I2 = 0%) and dias-
tolic blood pressure (Analysis 1.3.2 (5 studies, 186 participants):
MD -3.75 mm Hg, 95% CI -5.33 to -2.17; I2 = 0%). There was
no significant difference between the short-term and long-term
studies (systolic blood pressure: test for subgroup differences: Chi
2 = 0.80, df = 1 (P = 0.37); I² = 0%) (diastolic blood pressure: test
for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88); I2 = 0%).
A notable difference in blood pressure measurement techniques
between the studies related to use of 24 hour blood pressure in the
three short-term studies (Konishi 2001; LowSALT CKD Study
2012; Ruilope 1992a) and clinic blood pressure in four of the
five long-term studies (DUAAAL Study 2011; Fine 1997; Keven
2006; Vogt 2008). This may limit comparison by study duration.
Stage of chronic kidney disease
In early stages of CKD salt restriction reduced systolic blood pres-
sure (Analysis 2.2.1 (6 studies, 206 participants): MD -7.96 mm
Hg, 95%CI -10.74 to -5.17; I2 = 0%) and diastolic blood pressure
(Analysis 2.3.1 (6 studies, 206 participants): MD -3.40 mm Hg,
95% CI -4.86 to -1.94; I2 = 0%).
Fine 1997 included 20 peritoneal dialysis patients and reported
that with a low salt intervention there was a non-significant de-
crease in systolic blood pressure (Analysis 2.2.2: MD -9.00 mm
Hg, 95%CI -21.41 to 3.41) and diastolic blood pressure (Analysis
2.3.2: MD -5.00 mm Hg, 95% CI -11.32 to 1.32).
Keven 2006 included 32 post-transplant patients and reported
that with a low salt intervention there was a significant decrease in
systolic blood pressure Analysis 2.2.3: MD -16.00 mm Hg, 95%
CI -24.50 to -7.50) and diastolic blood pressure (Analysis 2.3.3:
MD -8.00 mm Hg, 95% CI -14.60 to -1.40).
Both fixed and random-effects models were used to ensure robust-
ness of the analyses. Reductions in systolic and diastolic blood
pressure did not change between these analyses.
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Measures of kidney function
Analyses of eGFR, SCr, CrCl, effective renal plasma flow and
filtration fraction were similar when analysed using the random-
effect method. Due to the small number of studies that reported
these outcomes, subgroup analyses were not possible.
Estimated glomerular filtration rate
There was no significant difference in eGFR between low and high
salt intake (Analysis 1.4 (2 studies, 68 participants): MD -1.14
mL/min/1.73 m2, 95% CI -4.38 to 2.11; I2 = 0%)
Creatinine clearance
There was no significant difference in CrCl between the low and
high salt intake groups (Analysis 1.5; 3 studies, 85 participants):
MD -4.60 mL/min, 95% CI -11.78 to 2.57; I2 = 0%).
DUAAAL Study 2011 (52 participants) reported CrCl as log-
transformed; these data could not be pooled with studies that re-
ported normally distributed CrCl. DUAAAL Study 2011 did not
report a significant change in CrCl with salt restriction (Analysis
1.6: MD -6.00 mL/min, 95% CI -20.55 to 8.55).
Serum creatinine
There was no significant difference in SCr between the low and
high salt intake groups (Analysis 1.7 (5 studies, 151 participants):
MD 5.14 µmol/L, 95% CI -8.98 to 19.26; I2 = 59%).
Effective renal plasma flow
Konishi 2001 (41 participants) reported no significant difference
in effective renal plasma flow between low and high salt intake
(Analysis 1.8: -33.00 mL/min, 95% CI -117.64 to 51.64)
Filtration fraction
Konishi 2001 (41 participants) reported no significant difference
in filtration fraction between low and high salt intake (Analysis
1.9: MD -1.00%, 95% CI -3.16 to 1.16).
Urinary protein excretion
Four studies (DUAAAL Study 2011; Konishi 2001; LowSALT
CKD Study 2012; Vogt 2008) presented changes in urinary pro-
tein; however, data could not be pooled for analysis. Available data
are presented in Table 1.
Salt restriction significantly reduced urinary protein excretion in
all studies that reported proteinuria as an outcome. Reductions
in 24 hour proteinuria ranged from 21% to 49%. Konishi 2001
and LowSALT CKD Study 2012, which were short-term studies,
reported reductions of 27% and 41% from the high salt to the low
salt period. The DUAAAL Study 2011 and Vogt 2008 (long-term
studies) reported reductions of 49% and 21%. LowSALT CKD
Study 2012 reported urinary albumin excretion and found that
24-hour urinary albumin was reduced by 51% from the high to
the low salt period.
Body weight and presence of oedema
Although body weight was decreased with salt restriction, this
change was not significant (Analysis 1.10 (5 studies, 139 partici-
pants): MD -1.46 kg; 95% CI -4.55 to 1.64; I2 = 0%).
Objective markers of fluid status were not routinely reported,
making it difficult to determine if body weight changes were at-
tributable to change in extracellular volume or body fat. LowSALT
CKDStudy 2012 (20 participants) reported no significant change
in extracellular volume (Analysis 1.11: MD -0.80 L, 95% CI -
3.09 to 1.49).
DUAAAL Study 2011 (52 participants) reported restricting salt
intake reduced the risk of oedema by 56% (Analysis 1.12: RR
0.44, 95% CI 0.21 to 0.93).
Body weight, extracellular fluid volume and presence of oedema
analyses did not change when analysis was performedwith a fixed-
effect model.
Renin-angiotensin-aldosterone system (RAAS) and N-
terminal pro-brain natriuretic peptide stimulation
(NT pro-BNP)
RAAS stimulation was reported as plasma renin activity, plasma
renin, plasma aldosterone and serum aldosterone. Salt restriction
significantly increased plasma renin activity (Analysis 1.13 (2 stud-
ies, 71 participants): MD 1.08 ng/mL/h, 95% CI 0.51 to 1.65; I
2 = 0%) and serum aldosterone (Analysis 1.14 (2 studies, 71 par-
ticipants): 6.20 ng/dL (95% CI 3.82 to 8.58; I2 = 0%).
LowSALT CKD Study 2012 (20 participants) reported plasma
renin and plasma aldosterone as non-normally distributed data;
therefore, these data were not pooled. Plasma renin was increased
by median 48 pmol/L (interquartile range (IQR) 23.5 to 70.5)
and plasma aldosterone by 53.8 mU/L (IQR 4.8 to 74.7) with salt
restriction (P < 0.001 for both analyses).
Vogt 2008 (32 participants) reported salt restriction significantly
decreased NT pro-BNP (Analysis 1.15: -29.00 pg/mL, 95% CI -
54.18 to -3.82). LowSALT CKD Study 2012 reported NT pro-
BNP as non-normally distributed data, and therefore, these data
were not pooled. The LowSALT CKD Study 2012 reported that
salt restriction reduced NT pro-BNP by 125 pg/mL (P < 0.05).
Results of these analyses did not change when performed using a
fixed-effect model.
Change in antihypertensive regimen
Antihypertensive medication dosage was significantly reduced
with low salt diet (Analysis 1.16 (2 studies, 52 participants): RR
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5.48, 95% CI 1.27 to 23.66; I2 = 0%). This may also reduce the
effect size of sodium restriction on blood pressure in these studies.
Adverse effects
Potential adverse effects reported included symptomatic hypoten-
sion and serum cholesterol. There was no significant change in
total cholesterol in relation to salt restriction (Analysis 1.17 (3
studies, 105 participants): MD -0.23 mmol/L, 95% CI -0.57 to
0.10; I2 = 0%).
There was a non-significant increase in symptomatic hypotension
with sodium restriction (Analysis 1.18 (2 studies, 72 participants):
RR 6.60, 95% CI 0.77 to 56.55; I2 = 0%). This is a potential
adverse effect associated with salt restriction, although one that
could be rectified by reducing the antihypertensive dose.
D I S C U S S I O N
Summary of main results
We found that reducing salt intake by approximately 6 g/d (100
mmol or 2300 mg sodium/d) lowered blood pressure by 9/4 mm
Hg in people with CKD. This is a clinically significant reduction
in blood pressure, comparable to expectations of administering a
single antihypertensive drug.
Studies of four weeks or longer showed greater reduction in blood
pressure than short-term studies: reductions of 10/4mmHgand7/
4 mmHg respectively. This may however be partially attributable
to methodological differences. In non-dialysed, non-transplanted
people with CKD, reducing salt intake reduced blood pressure by
8/3 mm Hg. We found only one study conducted in people on
dialysis (Fine 1997) and one in people who had undergone trans-
plantation (Keven 2006), making comparisons according to CKD
severity difficult. These studies reported reductions of 9/5 mmHg
with 3 g reduction in salt intake (50 mmol or 1150 mg sodium)
and 16/8 mm Hg with 8 g reduction in salt intake (130 mmol or
2990 mg sodium), respectively. It was found that eGFR, SCr and
CrCl were not significantly changed by salt restriction. Changes in
proteinuria data could not be entered into pooled analysis; how-
ever, studies consistently reported significant reductions with salt
restriction: 24 hour proteinuria or albuminuria reduction ranged
from 20% to 50%.
Overall completeness and applicability of
evidence
We aimed to evaluate the benefits and harms of altering dietary
salt intake for people with CKD. This review included a small
number of studies of relatively short duration. We could not assess
the effect of restricting salt intake on endpoints such as mortality
or cardiovascular events in people with CKD because there were
no RCTs of adequate size or duration to examine these outcomes.
This limitation has been noted in previous reviews in non-CKD
populations (Hooper 2002; Suckling 2010), and is likely due to the
practical aspects of achieving adherence to a sodium-restricted diet
in a long-term study (McMahon 2012a). Evidence for the longer-
term effects of sodium restriction on patient-level outcomes and
secondary risk markers (such as blood pressure and proteinuria) is
required.
Exploration of the differential effects of salt restriction by CKD
stage was limited due to the small number of included studies, par-
ticularly in the more advanced stages of CKD. Only one study in-
cluded post-transplant participants, and one was conducting with
people receiving peritoneal dialysis, and none in people receiving
haemodialysis. Salt restriction studies have been conducted in peo-
ple undergoing haemodialysis, but these are either observational
(Kayikcioglu 2009), non-randomised (Ang 1999; Osanai 2002)
or used a concomitant intervention in the sodium restricted group
(Rupp 1978) and were not eligible for inclusion in this review.
Subgroup analyses were not viable for outcomes other than blood
pressure due to the small number of studies measuring these out-
comes.
There was limited evidence for effects on albuminuria, fluid vol-
ume and arterial stiffness.
Controversy has arisen regarding the safety of long-term sustained
low sodium intake; studies have suggested an increased risk of hos-
pitalisation and mortality associated with very low sodium diet
(Kotchen 2013). Studies included in this review were not suffi-
ciently long to examine this effect.
Quality of the evidence
There was a considerable degree of heterogeneity among study
results. The small number of included studies limited exploration
of sources of heterogeneity, although a potential contributor was
the range of people with CKD who were represented - early stage
CKD (non-dialysis), dialysis, and transplant populations. Sodium
handling in people with mild CKD is likely to differ considerably
from those with severe kidney dysfunction, people on dialysis, and
kidney transplant recipients.
It is likely that differing magnitude and duration of salt restriction
and study methodology differences also impacted heterogeneity. A
previous analysis showed a dose-response relationship between salt
reduction and blood pressure reduction (He 2003); again, there
were too few included studies to explore this possibility for our
review.
An important difference was in relation to methods applied to
achieve salt-restricted diets. Studies that provided meals (Konishi
2001) or supplementary sodium (Fine 1997; LowSALT CKD
Study 2012; Ruilope 1992a) to manage sodium intake were at
lower risk of bias from dietary confounders because other di-
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etary factors were likely to remain stable over the study period
(McMahon 2012a). Previous research has found that when di-
etary advice is given about reducing sodium intake, other factors
such as energy and potassium intake can also change (Korhonen
2000). This means that studies relying on dietary advice to man-
age sodium intake (de Brito-Ashurst 2013; DUAAAL Study 2011;
Keven 2006; Vogt 2008) may be at a higher risk of bias from di-
etary confounders.
Measurement of potential dietary confounders was poor over-
all. Although it is widely accepted that potassium intake affects
blood pressure (Whelton 1997), only four of the six studies that
investigated blood pressure as an outcome measured potassium
intake either directly or indirectly. Both LowSALT CKD Study
2012 and de Brito-Ashurst 2013 reported data showing no change
in urinary potassium excretion with sodium restriction; however,
de Brito-Ashurst 2013 did not present specific data. DUAAAL
Study 2011 and Ruilope 1992a reported small, but significant, re-
ductions in urinary potassium excretion in the sodium-restricted
groups (3 to 4 mmol/d), which is likely to reflect reduction in uri-
nary volume. DUAAAL Study 2011 and LowSALT CKD Study
2012 reported modest, but significant increases, in serum potas-
sium with sodium restriction (increases of 0.1 and 0.3 mmol/L).
Body weight has also been reported to affect blood pressure (
Siebenhofer 2011). Change in body weight was reported by five
studies, and was reduced by mean -1.46 kg, although this was not
statistically significant (95%CI -4.55 to 1.64 kg). Given thatmost
studies did not report change in fluid status or energy intake, we
could not determine the degree to which body weight change was
due to reduction in fluid volume or body fat. The latter could
introduce bias by overestimating the effect of salt restriction on
blood pressure. Body weight is also related to proteinuria; two
of the four studies that reported proteinuria found that reduced
body weight with salt restriction did not measure fluid status. It
is therefore unknown if body weight reflected reduction in fluid,
body fat or other tissues (DUAAAL Study 2011; Vogt 2008).
Konishi 2001 did not measure body weight change. LowSALT
CKD Study 2012 reported reduction in body weight and fluid
volume - the reduction in body weight reflected reduction in fluid
volume.
A further confounder to proteinuria is change in protein intake.
Three of the four studies that reported proteinuria as an outcome
also measured a surrogate for protein intake. LowSALT CKD
Study 2012 reported no change in protein intake as assessed by
self-reported dietary history.DUAAALStudy 2011 andVogt 2008
reported urinary urea as a marker of protein intake and found
significantly reduced urinary urea in the sodium-restricted group
(40 to 50 mmol/24 h). This potentially reflected reduced protein
intake which may have overestimated the effect of salt restriction.
Although Konishi 2001 reported proteinuria as an outcome there
was no measurement of any protein intake marker.
Reduction in markers of dietary intake such as body weight could
indicate that consumption of other dietary nutrients may have de-
creased with salt restriction. Overall, quality of the included stud-
ies would have been greatly improved by measuring and account-
ing for change in potassium and protein intake, fluid volume or
both.
Other potential sources of bias in the included studies were un-
clear method of random sequence generation or allocation con-
cealment, lack of blinding or not disclosing if participants, inves-
tigators and/or outcome assessors were blinded introducing po-
tential for risk of performance or detection bias. It was difficult to
assess risk of bias for selective outcome reporting, because proto-
cols or trial registrations were unavailable for most studies. Where
these were available, most did not report all outcomes measured.
There were important differences in methodology between short-
(fewer than four weeks) and long-term studies (four weeks and
more) that limited subgroup analysis according to study dura-
tion. All shorter-term studies used 24 hour blood pressure, but
four of the five long-term studies used clinic blood pressure. Fur-
thermore, short-term studies used either supplemental sodium
(Konishi 2001; LowSALT CKD Study 2012) or full meal pro-
vision (Ruilope 1992a). Hence, it was likely that dietary con-
founders were more tightly controlled than in long-term studies
which mostly used dietary education methods. A limitation in
two of the three short-term studies was that neither employed a
washout period. Considering that these studies had intervention
durations of only one week, carry-over effect may have influenced
study results. Ruilope 1992a, a short-term study, began a new an-
tihypertensive medication on day one of the study, further increas-
ing risk of carry-over effect.
Potential biases in the review process
All efforts were made to minimise bias inherent in the review
process. Study inclusion and risk of bias assessment were carried
out by two authors working independently.
We contacted all study authors for additional information to in-
form our risk of bias assessment and received data for five of the
eight included studies (de Brito-Ashurst 2013; LowSALT CKD
Study 2012; Vogt 2008; Konishi 2001; DUAAAL Study 2011).
We obtained corrected data for some outcomes reported by de
Brito-Ashurst 2013 (systolic and diastolic blood pressure); how-
ever, incomplete data mean that standard deviation or P values for
change in total body water could not be provided. Body weight
data could not be meta-analysed because these were not statisti-
cally viable (MD -4 kg, 95% CI -4 to -1) and corrected data could
not be obtained (de Brito-Ashurst 2013).
Change from baseline data was not available for Keven 2006; nei-
ther were other data from which we could impute values for stan-
dard deviation of change.
Despite applying a search strategy to include both published and
unpublished studies, we were unable to include any unpublished
studies.
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Agreements and disagreements with other
studies or reviews
We found no previous published reviews of salt restriction in
people with CKD. Previous reviews investigating salt-restriction
have been conducted in people with normal kidney function, and
these consistently show that reducing dietary sodium intake re-
duces blood pressure, although magnitudes vary (Graudal 2011;
He 2013; Hooper 2002; Suckling 2010). Generally, dietary salt
reduction had a greater effect on people who are hypertensive
(Graudal 2011; He 2013; Hooper 2002). In this review, most
participants in the included studies were hypertensive; therefore,
subgroup analysis could not be conducted. Graudal 1998 iden-
tified that increased serum cholesterol level was an adverse effect
in a meta-analysis of sodium restriction. We found no significant
change in total cholesterol in relation to salt restriction in people
with CKD.
We found a reduction in blood pressure of 9/4 mm Hg with salt
reduction of approximately 100 mmol in people with CKD. This
is a larger benefit than reported elsewhere when a similar magni-
tude of salt reduction was investigated in the general population
(Graudal 2011) or people with diabetes (Suckling 2010) which
reported reductions of 5/3 mm Hg and 6/2 mm Hg in hyperten-
sive Caucasian and black people, and 5/3 mmHg in hypertensive
people with diabetes, respectively.
This comparison must be interpreted cautiously because it is dif-
ficult to make direct comparisons due to systematic differences
among populations (e.g. medication usage, baseline blood pres-
sure) and differences in quality and methodologies of included
studies. Nonetheless, we found that people with CKD may be
particularly salt-sensitive.
In a pooled meta-analysis of people with diabetes Suckling 2010
reported that CrCl was significantly reduced (-6.33 mL/min, 95%
CI -10.47 to -2.19) with salt restriction; eGFR was not signifi-
cantly changed (MD -1.92; 95% CI -4.49 to 0.64). We found
occurrence of CrCl, and did not reach statistical significance (MD
-4.60 mL/min, 95% CI -11.78 to 2.57) and that eGFR did not
change significantly with salt restriction. It is thought that reduc-
tions in CrCl with salt restriction occur as a result of hyperfiltra-
tion paradoxically decreasing risk of kidney disease (Allen 1997).
However, longer-term studies are needed to ascertain effects of salt
restriction on kidney function.
Salt restriction was found to consistently reduce proteinuria. This
was less consistent in the review by Suckling 2010 in people with
diabetes, with some studies reporting a significant reduction and
others finding no change. This difference was expected because
people with CKD are more susceptible to proteinuria. Albumin-
uria, a risk factor for kidney function decline and cardiovascular
disease (Suckling 2010; Jones-Burton 2006), was also reduced in
only included study that reported this outcome (LowSALT CKD
Study 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found that reducing dietary salt considerably reduced blood
pressure in people with CKD. Despite widespread antihyperten-
sive use, hypertension is prevalent among people with CKD. Salt
reduction represents a cost-effective and low risk strategy to reduce
blood pressure for people with CKD.
We found consistent evidence that dietary salt restriction reduced
proteinuria in people with CKD; reductions ranged from 20%
to 50%. If such reductions were maintained long term, this may
translate to clinically significant reductions in ESKD and cardio-
vascular events. We found a strong case for the benefits of salt
restriction in people with CKD. Current evidence-based clinical
guidelines recommend a sodium intake target of less than 6 g of
salt (100 mmol; 2300 mg sodium) per day for people with CKD,
although achieving long-term adherence to this target can be prob-
lematic. Referral to an accredited dietician who can provide in-
dividualised strategies to reduce sodium intake should be consid-
ered.
Implications for research
Most included studies were of short duration. Further research
to assess longer-term effects of salt restriction is warranted. High-
quality data on the effect of salt restriction on primary endpoints
such as mortality, progression to ESKD and cardiovascular events
would be ideal, but difficult to implement.Despite consistent data
from observational and non-randomised studies showing that salt
restriction reduced fluid volume in people with CKD, high quality
RCTs are lacking. Further research on the effect on other cardiac
and vascular abnormalities such as arterial stiffness, left ventricular
hypertrophy, inflammation and oxidative stress is warranted.
Future studies investigating salt restriction should employ meth-
ods that limit risk of bias due to dietary confounders where pos-
sible, and should take care to adequately measure dietary intake
of not only sodium, but other nutrients that may confound study
results. Research into long-term adherence to a sodium-restricted
diet may assist in translating these results into a practical setting.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
de Brito-Ashurst 2013
Methods • Study design: parallel RCT
• Time frame: June 2008 to July 2009
• Duration: 6 month intervention
Participants • Country: UK
• Setting: tertiary renal unit based in acute care hospital in East London
• Inclusion criteria: eGFR < 60 mL/min; mean BP > 130/80 mm Hg on at least
two clinic visits or taking antihypertensive medication; Bangladeshi origin; Attending
predialysis clinic
• Baseline characteristics
◦ CKD eGFR: low salt (41 ± 17 mL/min/1.73 m2); high salt (42 ± 15 mL/
min/1.73 m2)
◦ BP (systolic/diastolic): low salt (149 ± 15/85 ± 6 mm Hg); high salt (156 ±
11/85 ± 6 mm Hg)
◦ Sodium intake: low salt: (263 ± 54 mmol); high salt (259 ± 47 mmol)
• Number: low salt (25); high salt (23)
• Mean age ± SD (years): low salt (56 ± 11); high salt (61 ± 9)
• Sex (M/F): 28/20
• Exclusion criteria: on dialysis; BMI < 20 or > 35 kg/m2− urinary incontinence;
cognitive impairment or mental problems impairing ability to participate
Interventions Low salt group
• Reduced sodium intake by ongoing individualised dietary education (in person
and phone calls) and cooking lessons
• Duration: 26 weeks
High salt group
• Sodium intake: usual care (general low salt advice sent with doctor’s letter)
• Duration: 26 week
Co-interventions: nil
Outcomes • 24 h BP
• Total body water by body composition monitor
• Measurement of sodium intake: 24 h urine
• Measurement of confounders
◦ 24 h urinary potassium and creatinine
◦ Body weight change
◦ Physical activity levels measured using a pedometer
Notes • Funding: this study was funded by a PhD fellowship grant from the trustees of
Barts and The London Charitable Foundation. The analysis, interpretation of data,
generation of the manuscript and decision to submit for publication were carried out
independently of the funding body
• Additional data: provided by authors
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de Brito-Ashurst 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation to treatment was con-
ducted by the study statistician using com-
puter-generated random blocks with block
sizes between four and eight”
Allocation concealment (selection bias) Unclear risk “Group assignment given to the re-
searcher”. Further information not pro-
vided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Neither participants nor the dietitian
administering the intervention could be
blinded to treatment allocation. Data anal-
ysis was conducted by the study statistician
who was blinded to treatment allocation.”
Blinding of participants: No
Blinding of investigators: No
Blinding of outcomes assessors: No
Blinding of data assessors: Yes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for attrition unlikely to be related
to allocation
• 56 participants enrolled
• Unwilling to complete: 24 hour
urine collection (3), BP monitoring (2),
attend dietary education (1)
• Lost to follow-up: death (1);
emigration (1)
• Attrition by allocation: low salt
group (3); high salt group (5)
Selective reporting (reporting bias) Unclear risk No evidence of outcomes missing from re-
port; however, some data missing for cer-
tain outcomes (e.g. change for total body
water, P values for differences among base-
line data)
Carry over effect Low risk N/A
Bias from confounders Unclear risk Major confounders (potassium intake,
bodyweight change, physical activity)mea-
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de Brito-Ashurst 2013 (Continued)
sured and reported as ’unchanged’
Other Low risk Funding: PhD scholarship from charitable
trust
DUAAAL Study 2011
Methods • Study design: Double blind, cross-over RCT
• Time frame: April 2006 to October 2009
• Study duration (weeks): total (30); run in (6); interventions (6); no washout
Participants • Country: The Netherlands
• Setting: multicentre; outpatient clinics (3)
• Inclusion criteria: consecutive patients with kidney disease who visited the
nephrology outpatient clinic with non-diabetic nephropathy (confirmed by analysis of
blood and urine or kidney biopsy); CrCl ≥ 30 mL/min; BP > 125/75 mm Hg; residual
proteinuria > 1.0 g/d during ACE inhibition at maximal dose (lisinopril 40 mg/d);
aged > 18 years
• Baseline characteristics
◦ BP (systolic/diastolic): 131 ± 18/71 ± 12.5 mm Hg
• Number: randomised (54); analysed (52)
• Mean age ± SD: 51 ± 13 years
• Sex (M/F): 43/9 male (83%)
• Exclusion criteria: systolic BP > 180 mm Hg or diastolic BP > 110 mm Hg;
diabetes; renovascular hypertension; decrease in CrCl by ≥ 6 mL/min in previous year;
cardiovascular event in the previous 6 months; immunosuppressive treatment; regular
use (> 1 d/wk) of NSAIDs; pregnancy or breastfeeding
Interventions Low salt group
• Target sodium intake 50 mmol/d (individualised counselling by dietician)
• Duration: 12 weeks
High salt group
• Sodium intake: usual diet
• Duration: 12 weeks
Co-interventions
• Each participant was on lisinopril 40 mg/d for entire study and went through
four interventions for six weeks each in random order
◦ Usual salt, placebo*
◦ Usual salt valsartan 320 mg/d
◦ High salt, placebo*
◦ High salt valsartan 320 mg/d
◦ * used for analysis
Other information
• No other RAAS blockers. Additional antihypertensive drugs such as beta-
blockers, alpha-blockers, calcium channel blockers, and diuretics were allowed and
kept stable during the study
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DUAAAL Study 2011 (Continued)
Outcomes • 24 hour proteinuria
• Clinic BP
• Clinical evaluation of oedema
• Weight
• Serum markers (electrolytes, lipids, proteins, creatinine)
• Urinary electrolytes and CrCl
• Measurement of sodium intake: 24 hour urine
• Measurement of confounders
◦ Medication intake measured by pill counts
◦ Protein intake measured from urea excretion (Maroni formula)
Notes • Funding: Unrestricted grant from Novartis. No role in the design and conduct of
the study; collection, management, analysis, and interpretation of the data; and
preparation, review, or approval of the manuscript
• Additional data: provided by authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”An independent pharmacist randomised
these sequences, using a computer pro-
gram”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Dietary interventions were open label
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Additionally, we analysed the data for all
54 patients who were included (intention
to treat). As the effect estimates and con-
fidence intervals were very similar and the
statistical and clinical conclusions did not
change, we have not shown these data”
54 randomised, 2 withdrew after randomi-
sation; 52 included in analysis
Selective reporting (reporting bias) Low risk No evidence of reporting bias
Carry over effect Low risk Adequate intervention duration to reduce
risk of carry over effect
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DUAAAL Study 2011 (Continued)
Bias from confounders High risk Comparison of usual intake versus low
sodium intervention increases risk of di-
etary confounders - reduction in body
weight, potassium excretion and urinary
urea in low salt phase suggests potential
confounding
Other Unclear risk Funding: study supported by Novartis;
declaration of non-involvement by funder
Fine 1997
Methods • Study design: double blind, cross-over RCT
• Time frame: NS
• Study duration (weeks): total (18); run in/washout (3); intervention (6)
Participants • Country: Canada
• Setting: renal outpatients clinic
• Inclusion criteria: CAPD > 4 months
• Baseline data
◦ GFR: NS
◦ Baseline BP: NS
◦ Mean duration of dialysis: 15 ± 15 months
• Number: 20
• Mean age ± SD: 61 ± 13 years
• Sex (M/F): 14/6
• Exclusion criteria: diastolic BP > 100 mm Hg; difficulty staying oedema-free;
medication noncompliance; considered by researchers to be unable to keep an accurate
dietary history or record own BP; use of 4.25% dialysate in 75% on more of their usual
cycles; large geographical distance between unit and the patient’s home
Interventions Low salt diet
• Usual diet plus placebo
• Duration: 6 weeks
High salt diet
• Sodium intake: usual diet plus 60 mmol sodium capsule
• Duration: 6 weeks
Other information
• Co-interventions: none
• Dialysate sodium 132 mmol/L in all participants
Outcomes • Clinic BP (self-recorded)
• Weight (self-recorded)
• Measurement of sodium intake
◦ 24 hour urine + dialysate collection
◦ 3 day food record
◦ Change in dialysate regimen self-recorded
• Measurement of confounders
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Fine 1997 (Continued)
◦ Medication changes discussed but measurement not described
◦ Measurement of other dietary confounders not described
◦ Adherence to study medication not described
Notes • Funding: Baxter Healthcare Corporation and Kidney Foundation of Canada,
Manitoba Branch
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “By pharmacy”. Further information not
provided; however, low risk of bias due to
study design
Allocation concealment (selection bias) Low risk “Double blind” and medications packaged
by pharmacy. Probably concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Physician, patient, and study nurse were
blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Weight/BP: “Patients recorded own
weights and BP”
Objective outcome; however, introduced
attrition and could have unblinded alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Large degree of attrition but even in both
groups and well-explained
32 participants enrolled, 12 withdrew (6 in
each intervention), 20 completed and were
included for analysis
Selective reporting (reporting bias) Low risk No evidence of reporting bias
Carry over effect Low risk Sufficient washout
Bias from confounders Unclear risk Measurement of dietary confounders not
described
Other High risk Funding: Baxter Healthcare Corporation
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Keven 2006
Methods • Study design: parallel RCT
• Time frame: January 2004 to December 2004
• Study duration (weeks): total (12); intervention (12)
Participants • Country: Turkey
• Setting: NS
• Inclusion criteria: underwent kidney transplant between 1993 and 2002 and
continuing care at time of screening; stable allograft function at the time of evaluation
(SCr < 2.5 mg/dL); on antihypertensive treatment; residing in geographic proximity to
the institution
• Baseline characteristics
◦ Duration of transplant (years): Low salt (5.3 ± 3.1); high salt (7.2 ± 3.9)
◦ Baseline BP (systolic/diastolic): low salt (146 ± 21/89 ± 8 mm Hg); high salt
(140 ± 16/86 ± 8 mm Hg)
◦ Baseline sodium intake: 190 mmol
• Number: low salt (18); high salt (14)
• Mean age ± SD (years): low salt (40 ± 14); high salt (43 ± 9)
• Sex (M/F): 25/7
• Exclusion criteria: evidence of renal artery stenosis on Doppler ultrasonography
Interventions Low salt group
• Target sodium intake 80 to 100 mmol/d (counselling by dietician)
• Duration: 12 weeks
High salt group
• Sodium intake: assumed usual diet (information not provided)
• Duration: 12 weeks
Co-interventions
• Antihypertensive treatment (including dose/number of drugs) adjusted if systolic
BP > 140 or < 100 mm Hg, and/or diastolic BP > 90 mm Hg or < 70 mm Hg as
assessed by a blinded physician
Outcomes • Clinic BP
• Serum markers (electrolytes, creatinine)
• Measurement of sodium intake: 24 hour urine
• Measurement of confounders: medication changes recorded
Notes • Funding: NS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”. Further information not
provided. Considerable difference in base-
line BP likely to underestimate effect of in-
tervention with parallel design
Allocation concealment (selection bias) Unclear risk Not described
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Keven 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label dietary intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not specified
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition reasons explained; however, attri-
tion for each group not provided
35 participants began study, 3 withdrew
(noncompliance with study visits (1), long-
term hospitalisation secondary to chronic
diarrhoea (1), development of chronic al-
lograft nephropathy (1))
Selective reporting (reporting bias) Unclear risk No evidence of reporting bias; however,
study registration could not be located
Carry over effect Low risk Not applicable
Bias from confounders High risk Confounding factors not measured/de-
scribed (body weight, potassium, insuf-
ficient information provided about anti-
hypertensive medication changes). Highly
likely that other dietary factors may have
confounded results with unblinded, usual
intake versus low sodium, study design
Other Unclear risk Funding: NS
Konishi 2001
Methods • Study design: cross-over RCT
• Time frame: NS
• Duration of study (weeks): total (3); run in (1); interventions (1); no washout
Participants • Country: Japan
• Setting: NS
• Inclusion criteria: IgA nephropathy as diagnosed by percutaneous kidney biopsy
• Baseline characteristics
◦ GFR: NS
◦ BP: NS
• Number: 38
• Mean age ± SD: 45 ± 15 years
• Sex: 14/27
• Exclusion criteria: other kidney or heart disease; taking any medication
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Konishi 2001 (Continued)
Interventions Low salt group
• Sodium intake 87 mmol/d (meals provided)
• Duration: 1 week
High salt group
• Sodium intake 209 mmol/d (meals provided)
• Duration: 1 week
Other information
• Study diets contained the same amount of protein (1.2 g/kg body weight/d) and
calories (35 kcal/kg/d)
• Participants were asked to maintain usual levels of physical activity and to refrain
from drugs for 1 week before and during the study
• Co-interventions: none
Outcomes • 24 hour BP (hourly measurements)
• 24 hour proteinuria
• Serum markers (electrolytes, renin, aldosterone)
• Renal plasma flow, CrCl
• Measurement of sodium intake: 24 hour urine (3 days)
• Measurement of confounders: assumed medications recorded from medical charts
Notes • Funding: not reported
• Additional data: provided by authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information not provided
Allocation concealment (selection bias) Unclear risk Information not provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Information not provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Information not provided. However, given
nature of outcomes (objective and results
not available immediately)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition not provided
Selective reporting (reporting bias) Unclear risk No evidence of reporting bias; however,
study registration could not be located
Carry over effect Unclear risk Short interventionswith nowashout - carry
over effect may be present
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Konishi 2001 (Continued)
Bias from confounders Unclear risk Standardised meals were provided reduc-
ing risk of dietary confounders, but as
confounders (e.g. potassium intake, weight
loss) were not discussed, risk of bias is un-
clear
Other Unclear risk Funding not reported
LowSALT CKD Study 2012
Methods • Study design: cross-over, double blind RCT
• Time frame: NS
• Duration of study (weeks): total (6); run in/washout (1); interventions (2)
Participants • Setting: single centre
• Country: Australia
• Inclusion criteria: systolic BP 130 to 169 mmHg; diastolic BP > 70 mmHg; aged
at least 18 years
• Baseline characteristics
◦ CKD: Stage 3 to 4 non-dialysed, non-transplanted
◦ Baseline BP (systolic/diastolic): low salt (149 ± 15/85 ± 6 mm Hg); high salt
(156 ± 11/85 ± 6 mm Hg)
◦ Baseline sodium intake (mmol): low salt (263 ± 54); high salt (259 ± 47)
• Number: 20
• Mean age ± SD: 68.5 ± 11.0 years
• Sex (M/F): 15/5
• Exclusion criteria: receiving RRT (dialysis or transplant) or likely to within study
period; salt-wasting CKD (as diagnosed by nephrologist); prescribed > 1680 mg
sodium bicarbonate and unable to cease therapy for 6 weeks; pregnant or breastfeeding;
life expectancy < 6 months; current involvement in other intervention; unable to
comprehend study protocol
Interventions Low salt group
• 60 to 80 mmol sodium intake - achieved by dietary education from trained
dietician (goal 60 to 80 mmol/d), plus placebo tablets
• Duration: 2 weeks
High salt group
• 180 to 200 mmol sodium intake - low salt diet (goal 60 to 80 mmol/d) achieved
by dietary education plus 120 mmol of sodium capsules
• Duration: 2 weeks
Other details
• Aimed to keep intake of other nutrients stable
• Co-interventions: none
Outcomes • 24 hour BP (every 20 min during day at 30 min at night)
• 24 hour proteinuria and albuminuria
• Pulse wave velocity
• Augmentation index (pulse wave analysis)
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LowSALT CKD Study 2012 (Continued)
• eGFR
• Fluid status (bio-impedance spectroscopy using Body Composition Monitor)
• 24 hour urine output
• Weight
• N-terminal pro-brain natriuretic peptide (via blood sample)
• Thirst (via xerostomia Index)
• C-reactive protein and adipokines
• Stimulation of renin-angiotensin-aldosterone system (blood sample)
• Taste test study
• Barriers and enablers to adherence measured via beliefs about dietary compliance
scale and attitudes to dietary recommendations questionnaires
• Sodium intake measurement
◦ 24 hour urine
◦ Midstream urine sample
◦ Semi-quantitative dietary history forms (verified by study dieticians)
◦ Food-frequency questionnaire
• Measurement of confounders
◦ 24 hour urinary potassium and urea
◦ Body weight change
◦ Dietary history (verified by study dieticians) to assess protein, sodium and
energy intake
◦ Daily self-record of study medication intake
Notes • Funding: research grants from the Princess Alexandra Hospital Private Practice
Trust Fund and Kidney Health Australia. Study foods provided by Freedom Foods,
Norco, Real Foods, Carman’s Fine Foods, Sanitarium Health & Wellbeing Company,
Rosella, and Diego’s
• Additional data: provided by authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by an exter-
nal statistical consultant
Allocation concealment (selection bias) Low risk “Study medication was packaged offsite
and labeled with the study numbers and
intervention order”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Participants, investigators, and outcome
assessors were blinded to the allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Participants, investigators, and outcome
assessors were blinded to the results of all
outcomes.”
“Data analysis was initially performed
blinded to treatment order and then was
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LowSALT CKD Study 2012 (Continued)
performed unblinded to confirm treatment
order”
Blinding of participants: All outcomes
Blinding of investigators and outcome as-
sessors: Serum and urinary markers, 24
hour BP and clinic BP blinded. Arterial
stiffness (pulse wave velocity and analysis)
unblinded
Blinding of data assessors: Initial data anal-
ysis performed blinded to allocation and
urinary sodium data
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition balanced between intervention
periods and reasons for attrition well doc-
umented and unrelated to study results
Those who withdrew from the study did
not differ in age or sex, but had
significantly higher weight and body mass
index values compared with those who
completed the study
25 participants randomised; 5 withdrew;
visit schedule too demanding (3), hospi-
tal admission unrelated to study (1), symp-
toms related to pre-existing medical condi-
tion (1)
Selective reporting (reporting bias) Low risk Data for all outcomes available for inclu-
sion in review
Carry over effect Low risk “To test for ... variation due to treatment
order ... analysis of covariance was con-
ducted”
No relationship found significant differ-
ence. Data analysed for carry over effect
Bias from confounders Unclear risk Major confounding factors measured
(potassium intake, energy intake, protein
intake, body weight, medication changes)
and assessed for potential impact on out-
comes. Medication changes may have af-
fected outcomes, although likely to under-
estimate effect size
Other Low risk Funding by hospital trust and not-for-
profit organisation
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Ruilope 1992a
Methods • Study design: cross-over RCT
• Time frame: NS
• Duration of study (weeks): total (6); run in (4); interventions (1); no washout
Participants • Country: NS
• Setting: NS
• Inclusion criteria: essential hypertension
• Baseline characteristics
◦ BP (systolic/diastolic): 158.2 ± 29.1/99.9 ± 8.9 mm Hg
◦ GFR not reported
◦ “Mild renal insufficiency”, diagnostic criteria (NS); nephrosclerosis (4);
other clinical criteria (10)
• Number: 14
• Mean age ± SD: 63.5 ± 22.4 years
• Sex: NS
• Exclusion criteria: no other concurrent medical illness
Interventions Low salt group
• Sodium intake 68 mmol/d (17 mmol dietary intake plus 51 mmol supplement).
Further information not provided
• Duration: 1 week
High salt group
• Sodium intake 187 mmol/d (17 mmol dietary intake plus 170 mmol supplement)
. Further information not provided)
• Duration: 1 week
Other details
• Dietary intake target 60 mmol potassium/d
• Co-interventions: 240 mg verapamil through both interventions
Outcomes • 24 hour BP (every 20 to 30 min)
• Clinic BP
• 24 hour proteinuria
• Weight
• Measurement of sodium intake: 24 hour urine
• Measurement of confounders: urinary potassium
Notes • Funding: NS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised”. Further information not
provided
Allocation concealment (selection bias) Unclear risk Information not provided
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Ruilope 1992a (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Information not provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information not provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information not provided
Selective reporting (reporting bias) Unclear risk No evidence of reporting bias; however,
study registration not available
Carry over effect High risk Addition of antihypertensive medication
on study day 1; short study duration and
lack of washout meant that carry over effect
was likely
Bias from confounders Unclear risk Unable to assess using information pro-
vided; no indication of medication adher-
ence; difference in sodium intake larger
than intended suggesting some protocol
deviation
Other Unclear risk Funding NS
Vogt 2008
Methods • Study design: cross-over RCT
• Time frame: March 2004 to June 2006
• Duration of study (weeks): total (36); interventions (6); no washout
Participants • Country: The Netherlands
• Setting: outpatient renal clinic
• Inclusion criteria: stable proteinuria > 2 g/d and < 10 g/d; stable kidney function
(< 6 mL/min/y decline); aged 18 to 70 years
• Baseline characteristics
◦ CKD: CrCl ≥ 30 mL/min
◦ Systolic BP/diastolic BP: 131 ± 18/71 ± 12.5 mm Hg
• Number: 34
• Mean age ± SD: 50 ± 12 years
• Sex (M/F): 25/9
• Exclusion criteria: MAP > 100 mm Hg; serum K > 5.5 mmol/L; CVD (MI,
unstable angina, percutaneous transluminal coronary angioplasty, CABG, or stroke
within the last 6 months); contraindication for AT1-antagonist or diuretic use;
diabetes; frequent users of NSAID (> 2 doses/wk)
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Vogt 2008 (Continued)
Interventions Low salt group
• Target 50 mmol Na/d (individualised counselling by dietician)
• Duration: 6 weeks
High salt group
• Target 200 mmol Na/d
• Duration: 6 weeks
Other details
• Additional antihypertensive drugs except for RAAS-blocking agents or diuretics
were allowed for BP control and kept stable during the study
• Co-interventions: 6 weeks each with placebo, losartan, losartan plus
hydrochlorothiazide on high-sodium diet or low-sodium diet in random order during
18 weeks. After 18 weeks, participants changed diet and the three 6 week periods were
repeated. Placebo on high and low Na diet used for this review
Outcomes • 24 hour proteinuria
• Clinic BP
• Serum markers (creatinine, urea, cholesterol, triglycerides, total protein, albumin)
• N-terminal pro-brain natriuretic peptide
• Renin, aldosterone
• Uric acid
• Plasma vascular endothelial growth factor C
• Kidney Injury Molecule 1
• N-acetyl-beta-D-glucosaminidase
• Measurement of sodium intake: 24 hour urine
• Measurement of confounders: Urinary urea, weight
Notes • Funding: supported by Merck Sharp & Dohme (grant MSGP NETH-15-01)
• Additional data: provided by authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was conducted by pharma-
cists using a computer generated model
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Dietary interventions were open label
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lowattrition andunlikely to introduce bias
35 were randomised, one withdrew
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Vogt 2008 (Continued)
Selective reporting (reporting bias) Low risk No evidence of reporting bias
Carry over effect Low risk Sufficient intervention duration to avoid
carry over effect
Bias from confounders High risk Reduction in body weight (unable to de-
termine if fluid change) and urinary urea in
low salt phase may have confounded results
Other High risk Supported by Merck Sharp & Dohme
ACE - angiotensin-converting-enzyme; BMI - body mass index; BP - blood pressure; CABG - coronary artery bypass graft; CAPD -
continuous ambulatory peritoneal dialysis; CKD - chronic kidney disease; CrCl - creatinine clearance; CVD - cardiovascular disease;
eGFR - estimated glomerular filtration rate; ESKD - end-stage kidney disease; GFR - glomerular filtration rate; HD - haemodialysis;
IgA - immunoglobulin A; MAP - mean arterial pressure; MI - myocardial infarction; Na - sodium; NS - not stated; NSAID -
nonsteroidal anti-inflammatory drug; PD - peritoneal dialysis; RAAS - renin-angiotensin-aldosterone system; RCT - randomised
controlled trial; RRT - renal replacement therapy; SCr - serum creatinine
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
De Nicola 2000 No random allocation to low or high salt diet
Esnault 2005 Concomitant intervention
Forrester 2010 Not CKD population
Kauric-Klein 2012 Concomitant intervention
Mahmoodi 2011 No random allocation to low or high salt diet
Osanai 2002 No random allocation to low or high salt diet
Rupp 1978 Concomitant intervention
Suckling 2010b Not CKD population
Swift 2005 Not CKD population
CKD - chronic kidney disease
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Characteristics of studies awaiting assessment [ordered by study ID]
Hwang 2014
Methods • Study design: parallel, open label RCT
• Time frame: March 2012 to March 2013
• Duration of study: 8 weeks
Participants • Country: South Korea
• Setting: multicentre, outpatient renal clinics (7)
• Inclusion criteria: aged 19 to 75 years; systolic/diastolic BP ≥ 140/90 mm Hg and over, patients is newly
diagnosed with hypertension or is prescribed antihypertensive medications; verified at least twice to have albumin:
creatinine ratio of ≥ 30 mg/g in a spot urine sample with interval of 1 week or more in recent 6 months
• CKD: eGFR by Modification of Diet in Renal Disease equation ≥ 30 mL/min/1.73 m2
• Sample size: estimated 270
• Exclusion criteria: systolic/diastolic BP > 160/100 mm Hg; pregnant; serum potassium level > 5.5 mEq/L at
screening period; malignancy; acute cerebral infarction; acute myocardial infarction; unstable angina; PCI or CABG
in recent 6 months; diabetes mellitus; allergy to olmesartan; involved in other clinical study in recent 1 month or are
participated in screening period; taking medications of corticosteroid or immunosuppressant in a screening period
Interventions Low salt group
• Low salt diet via dietary education from dietician (one 30 minute phone call every week)
High salt group
• Education for low salt diet will be conducted as in office with brief communication with a patient and a
physician
Outcomes • Spot urine albumin to creatinine ratio
• Hb
• 24 hour urinary sodium excretion
• BP
Notes • Registered at: NCT00702312
Rodrigues Telini 2014
Methods • Study design: parallel, open-label RCT
• Time frame: April 2007 to February 2009
• Duration of study: 16 weeks
Participants • Country: Brazil
• Setting: NS
• Inclusion criteria: aged ≥ 18 y; haemodialysis for at least 90 days; CRP ≥ 0.7 mg/dL
• Number: low salt (21); high salt (18)
• Exclusion criteria: acute inflammatory processes confirmed by clinical criteria and/or complementary tests;
acute inflammatory diseases; tuberculosis use of antibiotics within the past two months; chronic inflammatory
diseases; neoplasia; chronic obstructive pulmonary disease; use of central venous catheter and positive HIV serology
Interventions Low salt group
• Reduction of 34 mmol sodium from usual intake
High salt group
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Rodrigues Telini 2014 (Continued)
• No intervention
Outcomes • C-reactive protein
• Interleukin-6
• Alpha tumour necrosis serum concentrations
Notes • Registered at: NCT01458808
BP - blood pressure; CRP - C-reactive protein; eGFR - estimated glomerular filtration rate; RCT - randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Clark-Cutaia 2013
Trial name or title Intervention to reduce dietary sodium in hemodialysis (BalanceWise-HD)
Methods • RCT testing a behavioral intervention to reduce dietary sodium intake
Participants • Sample size: 200 adult HD patients
• Inclusion criteria: aged ≥ 18 y; literacy; community-dwelling adults who have been receiving
maintenance dialysis for at least 3 months
• Exclusion criteria: illiteracy; non-English speakers; individuals who plan to move out of the area or
change dialysis centres within the next six months; life expectancy < 12 months; scheduled for a living
donor transplant; individuals who cannot see the PDA screen or use the stylus to make food selections from
the PDA screen, or who live in an institutional setting in which they would have limited control over their
dietary intake
Interventions • Intervention participants continue to receive routine dialysis care, as well as a 16 week dietary
counselling intervention based on Social Cognitive Theory. Dietary counselling is paired with Personal
Digital Assistant-based dietary self-monitoring.
• Behavioral: Social Cognitive Theory based dietary counselling paired with personal digital assistant
based self-monitoring.
• The intervention duration is 16 weeks. Intervention contacts are 2 x weekly for weeks 0 to 8, weekly
for weeks 9 to 12, and every other week for weeks 13 to 16.
• Personal digital assistant dietary records are used to provide targeted counselling and engaged the
participant in problem solving around dietary issues.
• Attention control participants continue to receive routine dialysis care. Attention control participants
view 5 computerised educational programs PowerPoint slides) that summarise HD diet in 5 modules evenly
over the 4-month study period. Attention control participants continue to receive routine dialysis care.
Attention control participants view 5 computerised educational programs PowerPoint slides) that
summarise the various elements of the HD diet. The 5 modules evenly over the 4 month study period
Outcomes • Interdialytic weight gain
• Dietary adherence (sodium intake) (3 x 24 hour diet recalls)
• Clinic BP
• Self-efficacy for restricting dietary sodium in HD
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Clark-Cutaia 2013 (Continued)
• Self-rated global health
• Haemodialysis symptoms (10 point scale)
• Barriers to dietary adherence (questionnaire)
• Experience with the haemodialysis diet and intervention (qualitative interview)
Starting date 01/09/2009
Contact information Linda J Hough, MPH, Susan Stark MS; University of Pittsburgh School of Medicine
Notes
NCT00141609
Trial name or title A study looking at the effects of a modest reduction in dietary salt intake on blood pressure control in
haemodialysis patients (haemodialysis salt reduction study)
Methods • Study design: double blind, cross over RCT. Single centre
• Duration of study: 8 weeks
Participants • Sample size: 20 (estimated)
• CKD: HD
• Inclusion criteria: haemodialysis/haemodiafiltration for ESKD > 3 months; clinically stable
• Exclusion criteria: significant intercurrent illness; systolic BP > 240 mm Hg or diastolic BP > 120 mm
Hg at enrolment; unstable BP whilst on haemodialysis; sodium profiled haemodialysis or haemodiafiltration
Interventions Low salt group
• Intervention: 100 mmol
High salt group
• Intervention: 170 to 200 mmol
Outcomes • Pre-dialysis systolic BP
• Post-dialysis ambulatory BP (24 hr)
• Thirst score
• Intradialytic weight gain
• Systemic vascular resistance
• Asymmetric dimethylarginine (ADMA)
Starting date April 2004
Contact information Principal investigator: Timothy WR Doulton
St George’s, University of London
Notes
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NCT00974636
Trial name or title Lowering salt intake in chronic kidney disease: a pilot randomized crossover trial (BIA)
Methods • Study design: open label, cross-over RCT. Single centre
• Duration of study (weeks): total (12); interventions (4); washout (2)
Participants • Number: 35
• CKD: Stages 3 and 4
• Inclusion criteria: aged ≥ 18 years and ≤ 85 years; willing and able to comply with all study
procedures; eGFR 20 to 60 mL/min/1.73 m2 and relatively stable clinical course; sitting systolic BP ≥ 100
mm Hg prior to study entry
• Exclusion criteria: recent acute illness (≤ 1 month) (minor ailments left to the site principal
investigator’s discretion); recent hospitalisation (≤ 1 month) (unless clearly for a minor elective procedure
unlikely to interfere with BIA measurements to the site principal investigator’s discretion); any psychological
condition (including alcoholism) that could interfere with the patient’s ability to comply with the study
protocol; baseline 24 hour urinary sodium excretion ≤ 100 mmol/d
• Amputation of a limb other than fingers or toes; pacemaker, defibrillator, implantable pump, artificial
joint, pins, plates or other types of metal objects in the body (other than dental fillings); coronary stents or
metal suture material in the heart; use of any investigational product or investigational medical device
within 30 days prior to screening, or requirement for any investigational agent prior to completion of all
scheduled study assessments; weight over 300 pounds (limitation for examination table); pregnancy or
lactation; salt wasting kidney disease; atrial fibrillation; any condition that in the view of the PI placed the
subject at high risk of poor treatment compliance or of not completing the study
Interventions Low salt group
• ≤ 85 mmol/d for two weeks
High salt group
• Usual intake for two weeks
Outcomes Change in volume status (intracellular, extracellular volume, and total body water) as measured by
bioimpedance analysis using both whole body and segmental techniques
Starting date May 2009
Contact information Principal investigator: Rajiv Saran, MD; University of Michigan
Notes
NCT01015313
Trial name or title Effects of intensified sodium management in hemodialysis patients
Methods • Study design: parallel, open label RCT. Multiple sites
• Duration of study: total (12 months)
Participants • Sample size: target (40)
• CKD: Ambulatory, clinically stable maintenance haemodialysis patients on three times weekly HD
regimen
• Inclusion criteria: willing and able to provide written, signed informed consent after the nature of the
study has been explained; willing and able to comply with all study procedures; aged ≥ 18 years
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NCT01015313 (Continued)
• Exclusion criteria: simultaneous participation in another clinical study except observational studies;
any psychological condition that could interfere with the patient’s ability to comply with the study protocol;
pregnancy; amputation of a limb; pacemaker, implantable pump, artificial joint; expectation that native
kidney function will recover; unable to verbally communicate in English or Spanish; scheduled for living
donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another centre
within the next 14 months; life expectancy < 15 months
Interventions Low salt group
• Dietary sodium restriction avoiding positive sodium balance during dialysis by
◦ aligning dialysate sodium with plasma sodium, and
◦ avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms
High salt group
• No intervention: standard care
Outcomes • Feasibility of intensive sodium management
• Hospitalisation
Starting date November 2009
Contact information Contact: Rebecca Apruzzese. rapruzzese@rriny.com
Notes
BP - blood pressure; CABG - coronary artery bypass graft; CKD - chronic kidney disease; eGFR - estimated glomerular filtration rate;
ESKD - end-stage kidney disease; Hb - haemoglobin; HD, haemodialysis; PCI - percutaneous coronary arterial intervention; RCT
- randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Net change with altering salt and change by duration
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Sodium excretion 8 434 Mean Difference (IV, Random, 95% CI) -105.86 [-119.20, -
92.51]
1.1 Short-term (< 4 weeks) 3 144 Mean Difference (IV, Random, 95% CI) -115.06 [-132.50, -
97.62]
1.2 Long-term (≥ 4 weeks) 5 290 Mean Difference (IV, Random, 95% CI) -99.11 [-117.31, -
80.92]
2 Systolic blood pressure 8 434 Mean Difference (IV, Random, 95% CI) -8.75 [-11.33, -6.16]
2.1 Short-term (< 4 weeks) 3 144 Mean Difference (IV, Random, 95% CI) -7.18 [-11.48, -2.89]
2.2 Long-term (≥ 4 weeks) 5 290 Mean Difference (IV, Random, 95% CI) -9.64 [-12.88, -6.40]
3 Diastolic blood pressure 8 434 Mean Difference (IV, Random, 95% CI) -3.70 [-5.09, -2.30]
3.1 Short-term (< 4 weeks) 3 144 Mean Difference (IV, Random, 95% CI) -3.50 [-6.48, -0.51]
3.2 Long-term (≥ 4 weeks) 5 290 Mean Difference (IV, Random, 95% CI) -3.75 [-5.33, -2.17]
4 eGFR [mL/min/1.73 m2] 2 88 Mean Difference (IV, Random, 95% CI) -1.14 [-4.38, 2.11]
5 Creatinine clearance 3 170 Mean Difference (IV, Random, 95% CI) -4.55 [-11.86, 2.75]
6 Log creatinine clearance 1 Mean Difference (IV, Random, 95% CI) Totals not selected
7 Serum creatinine 5 270 Mean Difference (IV, Random, 95% CI) 5.14 [-8.98, 19.26]
7.1 Short-term (< 4 weeks) 2 68 Mean Difference (IV, Random, 95% CI) 5.05 [-35.59, 45.70]
7.2 Long-term (≥ 4 weeks) 3 202 Mean Difference (IV, Random, 95% CI) -0.05 [-12.73, 12.
62]
8 Effective renal plasma flow 1 Mean Difference (IV, Random, 95% CI) Totals not selected
9 Filtration fraction (%) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
10 Weight 5 278 Mean Difference (IV, Random, 95% CI) -1.46 [-4.55, 1.64]
10.1 Short-term (< 4 weeks) 2 68 Mean Difference (IV, Random, 95% CI) -1.79 [-6.45, 2.87]
10.2 Long-term (≥ 4 weeks) 3 210 Mean Difference (IV, Random, 95% CI) -1.19 [-5.34, 2.96]
11 Extracellular fluid volume 1 Mean Difference (IV, Random, 95% CI) Totals not selected
12 Presence of oedema 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
13 Plasma renin activity 2 142 Mean Difference (IV, Random, 95% CI) 1.08 [0.51, 1.65]
14 Serum aldosterone 2 142 Mean Difference (IV, Random, 95% CI) 6.20 [3.82, 8.58]
15 Brain natriuretic peptide
(NT-Pro BNP)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
16 Reduction in antihypertensive
dose
2 72 Risk Ratio (M-H, Random, 95% CI) 5.48 [1.27, 23.66]
17 Total cholesterol 3 210 Mean Difference (IV, Random, 95% CI) -0.23 [-0.57, 0.10]
18 Symptomatic hypotension 2 144 Risk Ratio (M-H, Random, 95% CI) 5.95 [0.74, 48.11]
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Comparison 2. CKD stage
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Sodium excretion 8 434 Mean Difference (IV, Random, 95% CI) -105.86 [-119.20, -
92.51]
1.1 CKD 6 362 Mean Difference (IV, Random, 95% CI) -107.21 [-120.24, -
94.18]
1.2 Dialysis 1 40 Mean Difference (IV, Random, 95% CI) -52.0 [-113.06, 9.
06]
1.3 Post-transplant 1 32 Mean Difference (IV, Random, 95% CI) -131.0 [-194.21, -
67.79]
2 Systolic blood pressure 8 434 Mean Difference (IV, Random, 95% CI) -8.75 [-11.33, -6.16]
2.1 CKD 6 362 Mean Difference (IV, Random, 95% CI) -7.96 [-10.74, -5.17]
2.2 Dialysis 1 40 Mean Difference (IV, Random, 95% CI) -9.0 [-21.41, 3.41]
2.3 Post-transplant 1 32 Mean Difference (IV, Random, 95% CI) -16.0 [-24.50, -7.50]
3 Diastolic blood pressure 8 434 Mean Difference (IV, Random, 95% CI) -3.69 [-5.08, -2.29]
3.1 CKD 6 362 Mean Difference (IV, Random, 95% CI) -3.40 [-4.86, -1.94]
3.2 Dialysis 1 40 Mean Difference (IV, Random, 95% CI) -5.0 [-11.32, 1.32]
3.3 Post-transplant 1 32 Mean Difference (IV, Random, 95% CI) -8.0 [-14.60, -1.40]
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Analysis 1.1. Comparison 1 Net change with altering salt and change by duration, Outcome 1 Sodium
excretion.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 1 Sodium excretion
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/d]N Mean(SD)[mmol/d]IV,Random,95% CI IV,Random,95% CI
1 Short-term (< 4 weeks)
Konishi 2001 38 48 (14) 38 166 (37) 23.2 % -118.00 [ -130.58, -105.42 ]
LowSALT CKD Study 2012 20 85 (35) 20 182 (54) 12.7 % -97.00 [ -125.20, -68.80 ]
Ruilope 1992a 14 72.6 (39.1) 14 214.4 (83.5) 6.1 % -141.80 [ -190.10, -93.50 ]
Subtotal (95% CI) 72 72 41.9 % -115.06 [ -132.50, -97.62 ]
Heterogeneity: Tau2 = 87.21; Chi2 = 2.94, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 12.93 (P < 0.00001)
2 Long-term (≥ 4 weeks)
de Brito-Ashurst 2013 25 -122.5 (40.4688) 23 -13 (12.113) 20.1 % -109.50 [ -126.12, -92.88 ]
DUAAAL Study 2011 52 106 (50.5) 52 189 (57.7) 17.1 % -83.00 [ -103.84, -62.16 ]
Fine 1997 20 155 (108) 20 207 (88) 4.1 % -52.00 [ -113.06, 9.06 ]
Keven 2006 18 106 (48) 14 237 (113) 3.9 % -131.00 [ -194.21, -67.79 ]
Vogt 2008 33 90 (57.4) 33 200 (57.4) 12.9 % -110.00 [ -137.70, -82.30 ]
Subtotal (95% CI) 148 142 58.1 % -99.11 [ -117.31, -80.92 ]
Heterogeneity: Tau2 = 182.90; Chi2 = 7.61, df = 4 (P = 0.11); I2 =47%
Test for overall effect: Z = 10.68 (P < 0.00001)
Total (95% CI) 220 214 100.0 % -105.86 [ -119.20, -92.51 ]
Heterogeneity: Tau2 = 158.74; Chi2 = 14.21, df = 7 (P = 0.05); I2 =51%
Test for overall effect: Z = 15.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.54, df = 1 (P = 0.21), I2 =35%
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Analysis 1.2. Comparison 1 Net change with altering salt and change by duration, Outcome 2 Systolic blood
pressure.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 2 Systolic blood pressure
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[mm
Hg] N
Mean(SD)[mm
Hg] IV,Random,95% CI IV,Random,95% CI
1 Short-term (< 4 weeks)
Konishi 2001 38 115 (11.2) 38 121.6 (13.1) 22.3 % -6.60 [ -12.08, -1.12 ]
LowSALT CKD Study 2012 20 144.9 (13.1) 20 154.6 (11.9) 11.1 % -9.70 [ -17.46, -1.94 ]
Ruilope 1992a 14 146.1 (20.2) 14 148 (21.2) 2.8 % -1.90 [ -17.24, 13.44 ]
Subtotal (95% CI) 72 72 36.3 % -7.18 [ -11.48, -2.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0011)
2 Long-term (≥ 4 weeks)
de Brito-Ashurst 2013 25 -8.6 (6.9) 23 -0.6 (9.5) 29.9 % -8.00 [ -12.73, -3.27 ]
DUAAAL Study 2011 52 123 (16.6) 52 134 (20.2) 13.3 % -11.00 [ -18.11, -3.89 ]
Fine 1997 20 135 (19) 20 144 (21) 4.3 % -9.00 [ -21.41, 3.41 ]
Keven 2006 18 116 (11) 14 132 (13) 9.3 % -16.00 [ -24.50, -7.50 ]
Vogt 2008 33 137 (17.2) 33 143 (23) 7.0 % -6.00 [ -15.80, 3.80 ]
Subtotal (95% CI) 148 142 63.7 % -9.64 [ -12.88, -6.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.29, df = 4 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 5.83 (P < 0.00001)
Total (95% CI) 220 214 100.0 % -8.75 [ -11.33, -6.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.00, df = 7 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 6.63 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
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Analysis 1.3. Comparison 1 Net change with altering salt and change by duration, Outcome 3 Diastolic
blood pressure.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 3 Diastolic blood pressure
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[mm
Hg] N
Mean(SD)[mm
Hg] IV,Random,95% CI IV,Random,95% CI
1 Short-term (< 4 weeks)
Konishi 2001 38 75 (8) 38 79 (9) 13.2 % -4.00 [ -7.83, -0.17 ]
LowSALT CKD Study 2012 20 79.4 (9.4) 20 83.3 (9) 6.0 % -3.90 [ -9.60, 1.80 ]
Ruilope 1992a 14 90.3 (11.3) 14 90.3 (12.1) 2.6 % 0.0 [ -8.67, 8.67 ]
Subtotal (95% CI) 72 72 21.8 % -3.50 [ -6.48, -0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.30 (P = 0.022)
2 Long-term (≥ 4 weeks)
de Brito-Ashurst 2013 25 -4 (4.4) 23 -1 (2.1) 52.3 % -3.00 [ -4.93, -1.07 ]
DUAAAL Study 2011 52 73 (13) 52 80 (15) 6.7 % -7.00 [ -12.40, -1.60 ]
Fine 1997 20 77 (8) 20 82 (12) 4.9 % -5.00 [ -11.32, 1.32 ]
Keven 2006 18 72 (10) 14 80 (9) 4.5 % -8.00 [ -14.60, -1.40 ]
Vogt 2008 33 83 (6) 33 86 (11.5) 9.9 % -3.00 [ -7.43, 1.43 ]
Subtotal (95% CI) 148 142 78.2 % -3.75 [ -5.33, -2.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.83, df = 4 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 4.67 (P < 0.00001)
Total (95% CI) 220 214 100.0 % -3.70 [ -5.09, -2.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.56, df = 7 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 5.20 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 1.4. Comparison 1 Net change with altering salt and change by duration, Outcome 4 eGFR
[mL/min/1.73 m2].
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 4 eGFR [mL/min/1.73 m
2
]
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
de Brito-Ashurst 2013 23 3 (6.7063) 25 3.4 (5.8142) 82.9 % -0.40 [ -3.96, 3.16 ]
LowSALT CKD Study 2012 20 29 (12.2) 20 33.7 (13.1) 17.1 % -4.70 [ -12.55, 3.15 ]
Total (95% CI) 43 45 100.0 % -1.14 [ -4.38, 2.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Net change with altering salt and change by duration, Outcome 5 Creatinine
clearance.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 5 Creatinine clearance
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Konishi 2001 38 108 (23) 38 114 (25) 45.7 % -6.00 [ -16.80, 4.80 ]
Ruilope 1992a 14 62.7 (10.8) 14 67.3 (18.6) 42.0 % -4.60 [ -15.87, 6.67 ]
Vogt 2008 33 126 (40.2) 33 125 (46) 12.3 % 1.00 [ -19.84, 21.84 ]
Total (95% CI) 85 85 100.0 % -4.55 [ -11.86, 2.75 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Net change with altering salt and change by duration, Outcome 6 Log
creatinine clearance.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 6 Log creatinine clearance
Study or subgroup Low salt High salt
Mean
Difference
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
DUAAAL Study 2011 52 66 (35) 52 72 (40.5) -6.00 [ -20.55, 8.55 ]
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Analysis 1.7. Comparison 1 Net change with altering salt and change by duration, Outcome 7 Serum
creatinine.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 7 Serum creatinine
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[
mol/L] N
Mean(SD)[
mol/L] IV,Random,95% CI IV,Random,95% CI
1 Short-term (< 4 weeks)
LowSALT CKD Study 2012 20 194 (97) 20 223 (104) 4.5 % -29.00 [ -91.33, 33.33 ]
Ruilope 1992a 14 141.44 (8.84) 14 123.76 (8.84) 35.5 % 17.68 [ 11.13, 24.23 ]
Subtotal (95% CI) 34 34 40.0 % 5.05 [ -35.59, 45.70 ]
Heterogeneity: Tau2 = 578.30; Chi2 = 2.13, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Long-term (≥ 4 weeks)
DUAAAL Study 2011 52 149 (64.9) 52 137 (57.7) 18.5 % 12.00 [ -11.60, 35.60 ]
Keven 2006 18 118 (27.4) 14 129 (32.7) 20.5 % -11.00 [ -32.30, 10.30 ]
Vogt 2008 33 126 (40) 33 125 (46) 21.0 % 1.00 [ -19.80, 21.80 ]
Subtotal (95% CI) 103 99 60.0 % -0.05 [ -12.73, 12.62 ]
Heterogeneity: Tau2 = 1.64; Chi2 = 2.03, df = 2 (P = 0.36); I2 =1%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 137 133 100.0 % 5.14 [ -8.98, 19.26 ]
Heterogeneity: Tau2 = 135.17; Chi2 = 9.84, df = 4 (P = 0.04); I2 =59%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 1.8. Comparison 1 Net change with altering salt and change by duration, Outcome 8 Effective
renal plasma flow.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 8 Effective renal plasma flow
Study or subgroup Low salt High salt
Mean
Difference
Mean
Difference
N Mean(SD)[mL/min] N Mean(SD)[mL/min] IV,Random,95% CI IV,Random,95% CI
Konishi 2001 38 516 (199) 38 549 (192) -33.00 [ -120.92, 54.92 ]
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Analysis 1.9. Comparison 1 Net change with altering salt and change by duration, Outcome 9 Filtration
fraction (%).
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 9 Filtration fraction (%)
Study or subgroup Low salt High salt
Mean
Difference
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Konishi 2001 38 22 (5) 38 23 (5) -1.00 [ -3.25, 1.25 ]
-4 -2 0 2 4
Favours low salt Favours high salt
49Altered dietary salt intake for people with chronic kidney disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 Net change with altering salt and change by duration, Outcome 10 Weight.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 10 Weight
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N Mean(SD)[kg] N Mean(SD)[kg] IV,Random,95% CI IV,Random,95% CI
1 Short-term (< 4 weeks)
LowSALT CKD Study 2012 20 86 (12.2) 20 86.4 (12.6) 16.2 % -0.40 [ -8.09, 7.29 ]
Ruilope 1992a 14 68.3 (8.2) 14 70.9 (7.6) 28.0 % -2.60 [ -8.46, 3.26 ]
Subtotal (95% CI) 34 34 44.2 % -1.79 [ -6.45, 2.87 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Long-term (≥ 4 weeks)
DUAAAL Study 2011 52 87 (14.4) 52 89 (21.6) 19.3 % -2.00 [ -9.06, 5.06 ]
Fine 1997 20 72 (10) 20 72 (11) 22.6 % 0.0 [ -6.52, 6.52 ]
Vogt 2008 33 89 (17.2) 33 91 (17.2) 13.9 % -2.00 [ -10.30, 6.30 ]
Subtotal (95% CI) 105 105 55.8 % -1.19 [ -5.34, 2.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI) 139 139 100.0 % -1.46 [ -4.55, 1.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 1.11. Comparison 1 Net change with altering salt and change by duration, Outcome 11
Extracellular fluid volume.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 11 Extracellular fluid volume
Study or subgroup Low salt High salt
Mean
Difference
Mean
Difference
N Mean(SD)[L] N Mean(SD)[L] IV,Random,95% CI IV,Random,95% CI
LowSALT CKD Study 2012 20 19.2 (3.7) 20 20 (3.7) -0.80 [ -3.09, 1.49 ]
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Analysis 1.12. Comparison 1 Net change with altering salt and change by duration, Outcome 12 Presence
of oedema.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 12 Presence of oedema
Study or subgroup Low salt High salt Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DUAAAL Study 2011 8/52 18/52 0.44 [ 0.21, 0.93 ]
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Analysis 1.13. Comparison 1 Net change with altering salt and change by duration, Outcome 13 Plasma
renin activity.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 13 Plasma renin activity
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N Mean(SD)[ng/mL/h] N Mean(SD)[ng/mL/h] IV,Random,95% CI IV,Random,95% CI
Konishi 2001 38 1.7 (1.8) 38 0.6 (0.9) 79.6 % 1.10 [ 0.46, 1.74 ]
Vogt 2008 33 5.2 (2.9) 33 4.2 (2.3) 20.4 % 1.00 [ -0.26, 2.26 ]
Total (95% CI) 71 71 100.0 % 1.08 [ 0.51, 1.65 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Net change with altering salt and change by duration, Outcome 14 Serum
aldosterone.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 14 Serum aldosterone
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N Mean(SD)[ng/dL] N Mean(SD)[ng/dL] IV,Random,95% CI IV,Random,95% CI
Konishi 2001 38 13.9 (8.3) 38 7.1 (3.1) 71.4 % 6.80 [ 3.98, 9.62 ]
Vogt 2008 33 14 (9.8) 33 9.3 (8.6) 28.6 % 4.70 [ 0.25, 9.15 ]
Total (95% CI) 71 71 100.0 % 6.20 [ 3.82, 8.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 5.10 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Net change with altering salt and change by duration, Outcome 15 Brain
natriuretic peptide (NT-Pro BNP).
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 15 Brain natriuretic peptide (NT-Pro BNP)
Study or subgroup Low salt High salt
Mean
Difference
Mean
Difference
N Mean(SD)[pg/mL] N Mean(SD)[pg/mL] IV,Random,95% CI IV,Random,95% CI
Vogt 2008 32 62 (41) 32 91 (60) -29.00 [ -54.18, -3.82 ]
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Analysis 1.16. Comparison 1 Net change with altering salt and change by duration, Outcome 16 Reduction
in antihypertensive dose.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 16 Reduction in antihypertensive dose
Study or subgroup Low salt High salt Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Keven 2006 7/14 1/18 54.8 % 9.00 [ 1.25, 64.89 ]
LowSALT CKD Study 2012 3/20 1/20 45.2 % 3.00 [ 0.34, 26.45 ]
Total (95% CI) 34 38 100.0 % 5.48 [ 1.27, 23.66 ]
Total events: 10 (Low salt), 2 (High salt)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Net change with altering salt and change by duration, Outcome 17 Total
cholesterol.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 17 Total cholesterol
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L] IV,Random,95% CI IV,Random,95% CI
DUAAAL Study 2011 52 4.8 (0.7) 52 5.1 (1.4) 61.0 % -0.30 [ -0.73, 0.13 ]
LowSALT CKD Study 2012 20 4.09 (1.43) 20 4.12 (1.26) 15.8 % -0.03 [ -0.87, 0.81 ]
Vogt 2008 33 5.9 (1.1) 33 6.1 (1.7) 23.1 % -0.20 [ -0.89, 0.49 ]
Total (95% CI) 105 105 100.0 % -0.23 [ -0.57, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Net change with altering salt and change by duration, Outcome 18
Symptomatic hypotension.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 1 Net change with altering salt and change by duration
Outcome: 18 Symptomatic hypotension
Study or subgroup Low salt High salt Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DUAAAL Study 2011 2/52 0/52 48.1 % 5.00 [ 0.25, 101.68 ]
LowSALT CKD Study 2012 3/20 0/20 51.9 % 7.00 [ 0.38, 127.32 ]
Total (95% CI) 72 72 100.0 % 5.95 [ 0.74, 48.11 ]
Total events: 5 (Low salt), 0 (High salt)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.094)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 CKD stage, Outcome 1 Sodium excretion.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 2 CKD stage
Outcome: 1 Sodium excretion
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/d]N Mean(SD)[mmol/d]IV,Random,95% CI IV,Random,95% CI
1 CKD
de Brito-Ashurst 2013 25 -122.5 (40.4688) 23 -13 (12.113) 20.1 % -109.50 [ -126.12, -92.88 ]
DUAAAL Study 2011 52 106 (50.5) 52 189 (57.7) 17.1 % -83.00 [ -103.84, -62.16 ]
Konishi 2001 38 48 (14) 38 166 (37) 23.2 % -118.00 [ -130.58, -105.42 ]
LowSALT CKD Study 2012 20 85 (35) 20 182 (54) 12.7 % -97.00 [ -125.20, -68.80 ]
Ruilope 1992a 14 72.6 (39.1) 14 214.4 (83.5) 6.1 % -141.80 [ -190.10, -93.50 ]
Vogt 2008 33 90 (57.4) 33 200 (57.4) 12.9 % -110.00 [ -137.70, -82.30 ]
Subtotal (95% CI) 182 180 92.0 % -107.21 [ -120.24, -94.18 ]
Heterogeneity: Tau2 = 126.28; Chi2 = 10.42, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 16.13 (P < 0.00001)
2 Dialysis
Fine 1997 20 155 (108) 20 207 (88) 4.1 % -52.00 [ -113.06, 9.06 ]
Subtotal (95% CI) 20 20 4.1 % -52.00 [ -113.06, 9.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
3 Post-transplant
Keven 2006 18 106 (48) 14 237 (113) 3.9 % -131.00 [ -194.21, -67.79 ]
Subtotal (95% CI) 18 14 3.9 % -131.00 [ -194.21, -67.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000049)
Total (95% CI) 220 214 100.0 % -105.86 [ -119.20, -92.51 ]
Heterogeneity: Tau2 = 158.74; Chi2 = 14.21, df = 7 (P = 0.05); I2 =51%
Test for overall effect: Z = 15.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.64, df = 2 (P = 0.16), I2 =45%
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Analysis 2.2. Comparison 2 CKD stage, Outcome 2 Systolic blood pressure.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 2 CKD stage
Outcome: 2 Systolic blood pressure
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[mm
Hg] N
Mean(SD)[mm
Hg] IV,Random,95% CI IV,Random,95% CI
1 CKD
Ruilope 1992a 14 146.1 (20.2) 14 148 (21.2) 2.8 % -1.90 [ -17.24, 13.44 ]
Vogt 2008 33 137 (17.2) 33 143 (23) 7.0 % -6.00 [ -15.80, 3.80 ]
LowSALT CKD Study 2012 20 144.9 (13.1) 20 154.6 (11.9) 11.1 % -9.70 [ -17.46, -1.94 ]
DUAAAL Study 2011 52 123 (16.6) 52 134 (20.2) 13.3 % -11.00 [ -18.11, -3.89 ]
Konishi 2001 38 115 (11.2) 38 121.6 (13.1) 22.3 % -6.60 [ -12.08, -1.12 ]
de Brito-Ashurst 2013 25 -8.6 (6.9) 23 -0.6 (9.5) 29.9 % -8.00 [ -12.73, -3.27 ]
Subtotal (95% CI) 182 180 86.4 % -7.96 [ -10.74, -5.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 5 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 5.60 (P < 0.00001)
2 Dialysis
Fine 1997 20 135 (19) 20 144 (21) 4.3 % -9.00 [ -21.41, 3.41 ]
Subtotal (95% CI) 20 20 4.3 % -9.00 [ -21.41, 3.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
3 Post-transplant
Keven 2006 18 116 (11) 14 132 (13) 9.3 % -16.00 [ -24.50, -7.50 ]
Subtotal (95% CI) 18 14 9.3 % -16.00 [ -24.50, -7.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.69 (P = 0.00022)
Total (95% CI) 220 214 100.0 % -8.75 [ -11.33, -6.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.00, df = 7 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 6.63 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.11, df = 2 (P = 0.21), I2 =36%
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Analysis 2.3. Comparison 2 CKD stage, Outcome 3 Diastolic blood pressure.
Review: Altered dietary salt intake for people with chronic kidney disease
Comparison: 2 CKD stage
Outcome: 3 Diastolic blood pressure
Study or subgroup Low salt High salt
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[mm
Hg] N
Mean(SD)[mm
Hg] IV,Random,95% CI IV,Random,95% CI
1 CKD
Ruilope 1992a 14 90.3 (11) 14 90.1 (12) 2.7 % 0.20 [ -8.33, 8.73 ]
LowSALT CKD Study 2012 20 79.4 (9.4) 20 83.3 (9) 6.0 % -3.90 [ -9.60, 1.80 ]
DUAAAL Study 2011 52 73 (13) 52 80 (15) 6.6 % -7.00 [ -12.40, -1.60 ]
Vogt 2008 33 83 (5.7) 33 86 (11.5) 10.1 % -3.00 [ -7.38, 1.38 ]
Konishi 2001 38 75 (8) 38 79 (9) 13.2 % -4.00 [ -7.83, -0.17 ]
de Brito-Ashurst 2013 25 -4 (4.4) 23 -1 (2.1) 52.2 % -3.00 [ -4.93, -1.07 ]
Subtotal (95% CI) 182 180 90.7 % -3.40 [ -4.86, -1.94 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.72, df = 5 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 4.57 (P < 0.00001)
2 Dialysis
Fine 1997 20 77 (8) 20 82 (12) 4.8 % -5.00 [ -11.32, 1.32 ]
Subtotal (95% CI) 20 20 4.8 % -5.00 [ -11.32, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
3 Post-transplant
Keven 2006 18 72 (10) 14 80 (9) 4.4 % -8.00 [ -14.60, -1.40 ]
Subtotal (95% CI) 18 14 4.4 % -8.00 [ -14.60, -1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.018)
Total (95% CI) 220 214 100.0 % -3.69 [ -5.08, -2.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.67, df = 7 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 5.19 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.95, df = 2 (P = 0.38), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Measurement of urinary protein in included studies
Study Proteinuria
measurement
High salt Low salt Reduction Significance
DUAAAL Study
2011
Protein; geometric
mean (95%CI)mg/
d; 24 hour urine
1680 (1310 to
2140)
850 (660 to 1100) 49% P < 0.001
Protein to creati-
nine ratio; geomet-
ric mean (95% CI)
mg/mg
1.2 (0.9 to 1.5) 0.6 (0.4 to 0.8) 51% P < 0.01
Konishi 2001 Pro-
tein; median (IQR)
mg/d; 24 hour urine
509 (207 to 1916) 372 (142 to 1134) 27% P = 0.004
LowSALT CKD
Study 2012
Pro-
tein; median (IQR)
mg/d; 24 hour urine
835 (185 to 1600) 493 (123 to 1300) 40% P < 0.01
Albu-
min; median (IQR)
mg/d; 24 hour urine
291 (40 to 1000) 143 (16 to 889) 51% P < 0.001
Protein: creatinine;
median (IQR) g/
mol creatinine; 24
hour urine
68 (23 to 164) 41 (17 to 126) 60% P < 0.05
Albumin:creati-
nine median (IQR)
g/mol creatinine; 24
hour urine
27 (5 to 127) 9 (2 to 82) 67% P < 0.05
Vogt 2008 Protein; mean (SE)
mg/d; 24 hour urine
3800 (400) 3000 (300) 21% P < 0.05
Protein concentra-
tion; mean (SE) ng/
mL
591 (78) 518 (85) 12% P < 0.05
Protein to creatinine
ratio; mean (SE)
mg/mg
2.45 (0.27) 2.10 (0.36) 14% P < 0.05
CI - confidence interval; IQR - interquartile range; SE - standard error
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. sodium chloride:kw
2. ((sodium or salt) near/5 (low or high or alter* or reduce* or reducing or reduction or restrict* or intake* or diet*
or increas* or decreas* or change* or changing)):ti,ab,kw
3. (#1 OR #2)
4. “renal replacement therapy”:ti,ab,kw
5. (h*emodialysis or h*emofiltration or h*emodiafiltration):ti,ab,kw
6. dialysis:ti,ab,kw
7. (CAPD or CCPD or APD):ti,ab,kw
8. (“kidney disease” or “kidney diseases” or “renal disease” or “renal diseases”):ti,ab,kw
9. (chronic next kidney or chronic next renal):ti,ab,kw
10. ((kidney next failure) or (renal next failure)):ti,ab,kw
11. (“end-stage kidney” or “end-stage renal” or “endstage kidney” or “endstage renal”):ti,ab,kw
12. (ESRF or ESKF or ESRD or ESKD):ti,ab,kw
13. (CKF or CKD or CRF or CRD):ti,ab,kw
14. (predialysis or “pre-dialysis”):ti,ab,kw
15. (nephropath* or nephrit* or glomerulo*):ti,ab,kw
16. (glomerular next disease*):ti,ab,kw
17. (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16)
18. (#3 AND #17)
MEDLINE 1. exp Sodium Chloride/
2. Diet, Sodium Restricted/
3. ((sodium or salt) adj5 (low or high or alter* or reduce* or reduction or restrict* or intake* or diet* or increas* or
decreas* or change* or changing)).tw.
4. or/1-3
5. Renal Replacement Therapy/
6. exp Renal Dialysis/
7. (hemodialysis or haemodialysis).tw.
8. (hemofiltration or haemofiltration).tw.
9. (hemodiafiltration or haemodiafiltration).tw.
10. dialysis.tw.
11. (CAPD or CCPD or APD).tw.
12. exp Kidney Diseases/
13. (kidney disease* or renal disease*).tw.
14. (nephropath* or nephrit* or glomerulo* or glomerular disease*).tw.
15. (end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
16. (ESRF or ESKF or ESRD or ESKD).tw.
17. (chronic kidney or chronic renal).tw.
18. (CKF or CKD or CRF or CRD).tw.
19. (predialysis or pre-dialysis).tw.
20. or/5-19
21. and/4,20
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(Continued)
EMBASE 1. Sodium Chloride/
2. Salt Intake/
3. Sodium Restriction/
4. Sodium Intake/
5. ((sodium or salt) adj5 (low or high or alter* or reduce* or reduction or restrict* or intake* or diet* or increas* or
decreas* or change* or changing)).tw.
6. or/1-5
7. exp Renal Replacement Therapy/
8. (hemodialysis or haemodialysis).tw.
9. (hemofiltration or haemofiltration).tw.
10. (hemodiafiltration or haemodiafiltration).tw.
11. dialysis.tw.
12. (CAPD or CCPD or APD).tw.
13. exp Kidney Disease/
14. (kidney disease* or renal disease*).tw.
15. (nephrop* or nephrit* or glomerulo* or glomerular disease*).tw.
16. (chronic kidney or chronic renal).tw.
17. (CKF or CKD or CRF or CRD).tw.
18. (end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
19. (ESRF or ESKF or ESRD or ESKD).tw.
20. (predialysis or pre-dialysis).tw.
21. or/7-20
22. and/6,21
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
Low risk of bias:Randomisation method described that would not
allow investigator/participant to know or influence intervention
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(Continued)
quate concealment of allocations prior to assignment group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
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(Continued)
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
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(Continued)
High risk of bias:Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
C O N T R I B U T I O N S O F A U T H O R S
1. Draft the protocol: EM, KC, JB, DM
2. Study selection: EM, KC, JB
3. Extract data from studies: EM, KC
4. Enter data into RevMan: EM
5. Carry out the analysis: EM
6. Interpret the analysis: EM, KC, JB, DM
7. Draft the final review: EM, KC, JB, DM
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The outcome sodium excretion has been included.
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